
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau







(10) International Publication Number WO 2019/097219 A1

(51) International Patent Classification:

A61K 36/05 (2006.01)

C12N 1/12 (2006.01)

(21) International Application Number:

PCT/GB2018/053278

(22) International Filing Date:

13 November 2018 (13.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

1718822.8 14 November 2017 (14.11.2017) GB 1719440.8 23 November 2017 (23.11.2017) GB 1813776.0 23 August 2018 (23.08.2018) GB

- (71) Applicant: UNIVERSITY OF GREENWICH [GB/GB]; Old Royal Naval College, Park Row, Greenwich, London SE10 9LS (GB).
- (72) Inventors: HARVEY, Patricia Janine; c/o UNIVERSITY OF GREENWICH, Old Royal Naval College, Park Row, Greenwich, London SE10 9LS (GB). XU, Yanan; c/o UNIVERSITY OF GREENWICH, Old Royal Naval College, Park Row, Greenwich, London SE10 9LS (GB).
- (74) **Agent: BROOKES IP**; Windsor House, 6-10 Mount Ephraim Road, Tunbridge Wells Kent TN1 1EE (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## **Published:**

— with international search report (Art. 21(3))

### (54) Title: PRODUCTION OF DUNALIELLA

(57) **Abstract:** The present invention provides Dunaliellaalga, and extracts thereof, comprising increased levels of 9-cis- $\beta$ -carotene and/or increased levels of colourless carotenoids; and/or increased levels of  $\alpha$ - carotene, to processes for producing such Dunaliella alga, and to uses thereof.



#### PRODUCTION OF DUNALIELLA

#### **TECHNICAL FIELD**

The present invention relates to *Dunaliella* algae, and extracts thereof, comprising increased levels of 9-*cis* β-carotene and/or increased levels of colourless carotenoids and/or increased levels of α-carotene, to processes for producing such *Dunaliella* algae, and to uses thereof.

## **BACKGROUND**

10

15

20

Dunaliella is a green alga which is known to produce high concentrations of  $\beta$ -carotene, a naturally occurring pigment which has a variety of uses, including as a food colourant, an additive for cosmetics, and a nutritional or health supplement for veterinary and human use.

Cother natural sources of β-carotene include carrots and palm oil, however, these produce a significantly lower β-carotene content compared with *Dunaliella* algae. *D. salina* is considered the best commercial source of natural β-carotene in the world (Borowitzka M.; J. Appl. Phycol. 1995;7:3–15). β-Carotene exists in the *all-trans*, and in the 9-*cis* forms with the known natural sources producing β-carotene predominantly as the *all-trans* isomer. Synthetic methods for the production of β-carotene provide exclusively the *all-trans* isomer and there is no known method of converting *all-trans*-β-carotene to 9-*cis*-β-carotene. OsD27, a 9-*cis/all-trans* β-carotene isomerase, catalyses the reversible isomerization between 9-*cis*- and *all-trans* β-carotene but conversion of 9-*cis* into *all-trans* β-carotene is the preferred reaction (Bruno, M. & Al-Babili, S., 2016, Planta, 243(6), pp.1429–1440).

25 Chemical structures of A) 9-cis- $\beta$ -carotene and B) all-trans- $\beta$ -carotene

15

20

PCT/GB2018/053278

Therapeutic uses of *Dunaliella salina bardawil* have been proposed: US 2010/0221348 A1 discusses the use of *Dunaliella salina bardawil* powder in the treatment of atherosclerosis and/or diabetes mellitus. Shaish *et al* (The alga *Dunaliella*: physiology, genomics and biotechnology,
ISBN 1578085454) hypothesize that the beneficial effects of *Dunaliella salina bardawil* on atherosclerosis is due to its high content of 9-*cis*- β-carotene. A clinical trial to test the effect of *Dunaliella salina barawil* on psoriasis is discussed in Greenberger *et al* (J. Am. Coll. Nutr., 2012, Oct, 31(5), 320-326). Trials investigating the effect of *Dunaliella salina bardawil* on retinal dystrophy and retinitis pigmentosa are discussed in Rotenstreich *et al* (Br. J. Opthalmol., 2010, May, 94(5), 616-621 and JAMA Opthalmol., 2013, Aug, 131(8), 985-92).

The major *all-trans* isomer has low solubility in aqueous solvent systems and tends to form crystals or precipitate, requiring formulation in oil based systems or emulsions, and thus limiting the industrial and clinical utility of *all-trans*  $\beta$ -carotene. The minor  $\theta$ -cis  $\beta$ -carotene has been found to dissolve crystalline *all-trans*  $\beta$ -carotene and to reduce the tendency of the *all-trans* form to precipitate. It would therefore be an advantage to produce  $\beta$ -carotene comprising predominantly the  $\theta$ -cis isomer, which  $\beta$ -carotene can be more easily formulated. However, extraction of natural  $\beta$ -carotene from *Dunaliella* followed by purification to increase the ratio of  $\theta$ -cis: *all-trans*  $\beta$ -carotene is currently the only known commercial method for producing preparations with a high  $\theta$ -cis  $\theta$ -carotene content, as discussed in US Patent No. 5,612,485 and European Patent Application No. EP0933359. A recent paper Sher *et al*, 2018 (Scientific Reports (2018) 8:6130) discusses a synthetic method for the preparation of  $\theta$ -cis-beta-carotene.

Dunaliella algae are also known to produce significant concentrations of the colourless carotenoids phytoene (IUPAC name (6E,10E,14E,16Z,18E,22E,26E)-2,6,10,14,19,23,27,31-25 octamethyldotriaconta-2,6,10,14,16,18,22,26,30-nonaene) and phytofluene (IUPAC name (6E, 10E, 12E, 14E, 16E, 18E, 22E, 26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,10,12,14,16,18,22,26,30-decaene), precursors in the biosynthesis of all carotenoids. Phytoene and phytofluene are rarities among carotenoids due to their lower number of conjugated double bonds, as a result of which they absorb maximally in the UV region, with phytoene absorbing 30 maximally in the UVB region and phytofluene in the UVA region. The compounds, which may be ingested or topically applied, are of great interest in the nutricosmetic field for their skin health and aesthetic benefits. Meléndez-Martínez et al 2018 (Journal of Food Composition and Analysis, 67, 91-103) discusses health and cosmetic benefits of phytoene and pytofluene. A review by Meléndez-Martínez et al 2015 (Archives of Biochemistry and Biophysics, 2015, 572, 188-200) 35 discussed the possible beneficial effect of phytoene and phytofluene, concluding that these

5

10

15

20

compounds may provide antioxidant activity, anticarcinogenic activity, anti-inflammatory activity, or protection against UVR-induced damage.

Chemical structures of (A) phytoene and (B) phytofluene:

Ben-Amotz et al (J Phycol (2987) 23:176–181) reported an increase in the phytoene content, and corresponding decrease in the  $\beta$ -carotene content, of *Dunaliella bardawil* treated with the herbicide norflurazon, a phytoene desaturase inhibitor.

Dunaliella algae are also known to produce significant concentrations of α-carotene (IUPAC name 1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohex-2-en-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene): α-carotene has proven anti-metastatic action, which is not associated with provitamin A activity (Liu *et al.*; J Nutr Biochem. 2015 Jun;26(6):607-15.). The structure of α-carotene is shown below:

# SUMMARY OF THE INVENTION

The invention provides a *Dunaliella* alga, or extract thereof, comprising

- i. an increased 9-cis  $\beta$ -carotene content and/or
- ii. an increased colourless carotenoid content; and/or
- iii. an increased α-carotene content:

when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

- 25 The invention further provides a powdered *Dunaliella* alga, or extract thereof, comprising:
  - i. an increased 9-cis  $\beta$ -carotene content and/or
  - ii. an increased colourless carotenoid content; and/or
  - iii. an increased α-carotene content;

WO 2019/097219 PCT/GB2018/053278 4

when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

The invention further provides *Dunaliella* alga, or extract thereof, or a powdered *Dunaliella* alga, or extract thereof; comprising a 9-cis β-carotene content of 60 wt % of total carotenoids or greater.

The invention further provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof, comprising a colourless carotenoid content of 10 wt % of total carotenoids or greater.

10

20

35

5

The invention further provides a process for the preparation of a *Dunaliella* alga comprising exposing the Dunaliella alga to light of wavelength 500-1000nm; and/or eliminating light of wavelength less than 500nm (blue light).

- 15 The invention further provides the use of a *Dunaliella* alga or extract thereof, or a powdered Dunaliella alga or extract thereof, as a food colourant or food ingredient; or as a health supplement, or in a cosmetic composition, wherein the *Dunaliella* alga, or extract thereof, comprises
  - i. an increased 9-cis β-carotene content and/or
  - an increased colourless carotenoid content; and/or ii.
  - iii. an increased α-carotene content;

when compared to a Dunaliella alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

- 25 The invention further provides a *Dunaliella* alga or extract thereof, or a powdered *Dunaliella* alga or extract thereof, for use in therapy, wherein the *Dunaliella* alga, or extract thereof, comprises
  - i. an increased 9-cis β-carotene content and/or
  - ii. an increased colourless carotenoid content; and/or
  - iii. an increased α-carotene content;
- when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural 30 light or white light conditions.

The invention further provides a composition comprising: a) a *Dunaliella* alga, or extract thereof; or a powdered Dunaliella alga, or extract thereof and b) a pharmaceutically acceptable excipient, wherein the *Dunaliella* alga, or extract thereof, comprises

- i. an increased 9-cis β-carotene content and/or
- ii. an increased colourless carotenoid content; and/or

iii. an increased  $\alpha$ -carotene content;

when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

The invention further provides a process for the preparation of a *Dunaliella* alga comprising treating the *Dunaliella* alga by application of a herbicide selected from the group consisting of amino acid synthesis inhibitors, growth regulators, nitrogen metabolism inhibitor, pigment inhibitors, seedling root growth inhibitors, seedling shoot growth inhibitors, cell wall synthesis inhibitors, mitosis microtubule organisation inhibitors, and combinations thereof.

10

25

30

35

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1** shows HPLC profiles at 450 nm of carotenoid extracts from *Dunaliella salina* exposed to continuous (A) white light, (B) red light and (C) blue light, each at 1000 μmol m<sup>-2</sup>s<sup>-1</sup> for 48 hours.

- Figure 2 shows the effect of different light treatments on (A) the ratio of 9-cis and all-trans β-carotene, (B) the cellular content of 9-cis β-carotene and all-trans β-carotene, (C) the amount of 9-cis β-carotene as a % of the total amount of carotenoid in Dunaliella salina when cultivated to early orange phase until light treatment (T0) and then subjected to different light treatments for 48 hours.
- Figure 3 shows the effect of different light treatments on (A) the cellular content of total carotenoids and chlorophyll, and (B) the cellular content of phytoene and *all-trans* α-carotene in *Dunaliella salina* when cultivated to early orange phase until light treatment (T0) and then subjected to different light treatments for 48 hours.
  - Figure 4 shows the effect of different light treatments on (A) the cellular content of 9-cis β-carotene and all-trans β-carotene, and (B) the ratio of 9-cis and all-trans β-carotene in Dunaliella salina when cultivated to mid-log phase (green phase) of growth until light treatment (T0) and then subjected to different light treatments.
  - Figure 5 shows the effect of different light treatments on (A) the cellular content of chlorophyll and total carotenoids, (B) the ratio of total carotenoids to total chlorophyll and (C) the cellular content of phytoene and *all-trans*  $\alpha$ -carotene in *Dunaliella salina* when cultivated to mid-log phase of growth until light treatment (T0) and then subjected to different light treatments.
  - Figure 6 shows the cellular content of (A) 9-cis β-carotene, and of (B) all-trans β-carotene, (C) the ratio of 9-cis and all-trans β-carotene, (D) the cellular content of phytoene and (E) the cellular content of all-trans α-carotene in Dunaliella salina treated with either continuous blue or red LED light at three different light intensities.

10

20

25

**Figure 7** shows the cellular content of (A) total carotenoids and (B) chlorophyll, and (C) the ratio of total carotenoids to total chlorophyll in *Dunaliella salina* treated with either continuous blue or red LED light at three different light intensities.

Figure 8 shows the effect of temperature on the cellular content of 9-cis β-carotene and all-trans
β-carotene (A) and the ratios of 9-cis and all-trans β-carotene (B) in Dunaliella salina cells exposed to red or blue LED light.

**Figure 9** shows the light properties of typical filters that may be used to transmit red light, such as: (purchased from Lee Filters) (A) 26 Bright red, (B) 27 Medium Red, and (C)787 Marius Red; and of typical filters that eliminate blue light, such as: (purchased from Lee Filters), (D) 105 Orange and (E) 010 Medium Yellow. Figure 9 (F) shows the typical relative spectral power distribution of white, blue and red LED lights.

Figure 10 shows the effects of exposure of *all-trans*  $\beta$ -carotene to red light under nitrogen (A) or in air (B) or to blue light under air or nitrogen (C).

Figure 11 shows the classification of *Dunaliella* strains.

Figure 12 shows the effect of different white, dark and red light cycles applied to *D. salina* cultures over 72h on the production of *9-cis-* and *all-trans* β-carotenes and total carotenoids. Compensation for the intensity of light emitted by LED lights may be required when red filters are applied as covers to LED lights.

Figure 13 shows the effect of red light, far-red light of 730 nm, and light of 830 nm applied to D. salina cultures for 48 h on the ratio of 9-cis: all-trans β-carotene. Both far red light and red light increase the 9-cis/all-trans ratio compared to white light alone.

Figure 14 shows the effect of cultivating D. salina under different red/dark cycles of increasing red light cycle time on cell density (A), cellular content of total carotenoids (B), ratio of carotenoids:chlorophyll (C), cellular content of  $\theta$ -cis  $\beta$ -carotene (D) and  $\theta$ -cis: all-trans  $\beta$ -carotene ratio (E). The data show that continuous red light applied over 140 h reduces chlorophyll content but increases cell density, and total carotenoid content especially  $\theta$ -cis  $\theta$ -carotene content.

Figure 15 shows the effect of treating *D. salina* cultures at 25 °C under either white LED light or red LED light in the presence of a phytoene desaturase inhibitor such as norflurazon.

Figure 16 shows the effect of cultivation of *D. salina* in the presence of chlorpropham.

Figure 17 shows the effect of cultivation of *D. salina* in the presence of the herbicides aminopyralid, carbetamide, and chlorsulfuron (cell division inhibitors), and glyphosate (phytochrome inhibitor).

**Figure 18** provides data to substantiate the identity of phytoene and phytofluene in cultures of *D. salina*.

Figure 19 illustrates the carotenoid biosynthetic pathway.

#### DETAILED DESCRIPTION

The inventors have surprisingly found that when exposed to red light (light of wavelength approximately 500 to 700 nm), eliminating blue light (light of wavelength less than 500 nm), green Dunaliella alga produces an increased content of all carotenoids, including phytoene, α-carotene and  $\beta$ -carotene, compared with the content produced by *Dunaliella* algae cultivated under normal white light (for example natural sun light). Alternatively, the *Dunaliella* alga may be exposed to red light of approximately 500 nm -700 nm and/or far-red light, and/or infrared light of wavelength approximately 700-1000 nm, preferably of wavelength approximately 500 nm to less than 830 nm. In particular, the ratio of 9-cis: all-trans- $\beta$ -carotene is increased, therefore providing an improved yield of  $\beta$ -carotene product which has the additional advantage of being easier to formulate and administer due to the higher 9-cis: all-trans- $\beta$ -carotene ratio. The relative increase in ratio of 9cis: all-trans β-carotene on exposure to red light compared to white light is even greater using early-orange phase algae and even greater still when Dunaliella algae are cultivated during red light exposure under cool temperatures (for example 15 °C compared to 25 °C). Light filters that blocked out blue light wavelengths (400 nm-500 nm) from white light were also found to be effective in increasing the amount of 9-cis  $\beta$ -carotene and the ratio of 9-cis: all-trans  $\beta$ -carotene. In contrast, exposure to blue light decreased the amount of 9-cis  $\beta$ -carotene and the ratio of 9-cis: all-trans β-carotene produced by the Dunaliella alga. Furthermore, when cultivated under natural light, the properties of the Dunaliella alga vary seasonally, for example in content of carotenoids and/or colour. Such seasonal variation is reduced or eliminated when the *Dunaliella* alga is exposed to red light.

In embodiment 1, the invention provides a Dunaliella alga, or extract thereof, comprising

- i. an increased 9-cis β-carotene content and/or
  - ii. an increased colourless carotenoid content; and/or
  - iii. an increased α-carotene content;

when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

30

10

15

20

In embodiment 2, the invention provides a powdered *Dunaliella* alga, or extract thereof, comprising:

- i. an increased 9-cis  $\beta$ -carotene content and/or
- ii. an increased colourless carotenoid content; and/or
- 35 iii. an increased  $\alpha$ -carotene content;

when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

In embodiment 3, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; comprising a *9-cis*  $\beta$ -carotene content of 60 wt % of total carotenoids or greater.

5

In embodiment 4, the invention provides a *Dunaliella* alga, or extract thereof according to embodiment 1; or a powdered *Dunaliella* alga, or extract thereof according to embodiment 2; wherein the 9-cis  $\beta$ -carotene content is 60 wt % of total carotenoids or greater.

In embodiment 5, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof, according to any preceding embodiment, wherein the *9-cis* β-carotene content is 65 wt % of total carotenoids or greater.

In embodiment 6, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the *9-cis* β-carotene content is 70 wt % of total carotenoids or greater

In embodiment 7, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the *9-cis* β-carotene content is 75 wt % of total carotenoids or greater.

In embodiment 8, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the  $\beta$ -carotene has a *9-cis*: *all-trans* ratio of 1.2 or greater.

25

15

20

In embodiment 9, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the  $\beta$ -carotene has a *9-cis*: *all-trans* ratio of 1.5 or greater.

In embodiment 10, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the  $\beta$ -carotene has a *9-cis*: *all-trans* ratio 2.0 or greater.

In embodiment 11, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered 35 *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the  $\beta$ -carotene has a *9-cis*: *all-trans* ratio 3.0 or greater. In embodiment 12, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; comprising a colourless carotenoid content of 10 wt % of total carotenoids or greater.

In embodiment 13, the invention a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the colourless carotenoid content is 11 wt% or greater.

In embodiment 14, the invention a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the colourless carotenoid content is 12 wt % or greater.

In embodiment 15, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the 9-cis  $\beta$ -carotene content is 60 wt% of total carotenoids or greater and the colourless carotenoid content is 10 wt % or greater of total carotenoids.

15

20

25

30

35

In embodiment 16, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the 9-cis  $\beta$ -carotene content is 60 wt% of total carotenoids or greater and the colourless carotenoid content is 11 wt% or greater of total carotenoids.

In embodiment 17, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; wherein the *9-cis* β-carotene content is 30 wt% of total carotenoids or greater and the colourless carotenoid content is 40 wt % or greater of total carotenoids.

In embodiment 18, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; wherein the 9-cis  $\beta$ -carotene content is 60 wt% of total carotenoids or greater and the colourless carotenoid content is 4 wt % or greater of total carotenoids.

In embodiment 19, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; wherein the 9-cis  $\beta$ -carotene content is 35 wt% of total carotenoids or greater and the colourless carotenoid content is 45 wt % or greater of total carotenoids.

WO 2019/097219 PCT/GB2018/053278 10

In embodiment 20, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered Dunaliella alga, or extract thereof, according to any preceding embodiment, wherein the colourless carotenoid content is the combined content of phytoene and phytofluene.

In embodiment 21, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered Dunaliella alga, or extract thereof; according to any preceding embodiment, comprising a phytoene content of 10 wt % of total carotenoids or greater.

10

5

In embodiment 22, the invention provides a *Dunaliella* alga, or extract thereof, or a powdered Dunaliella alga, or extract thereof, according to any preceding embodiment, comprising a phytoene content of 11 wt % of total carotenoids or greater.

15 In embodiment 23, the invention provides a *Dunaliella* alga, or extract thereof, or a powdered Dunaliella alga, or extract thereof, according to any preceding embodiment, comprising a phytoene content of 12 wt % of total carotenoids or greater.

In embodiment 24, the invention provides a *Dunaliella* alga, or extract thereof, or a powdered 20 Dunaliella alga, or extract thereof, optionally according to any preceding embodiment, comprising a phytoene content of 15 wt % of total carotenoids or greater.

In embodiment 25, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered Dunaliella alga, or extract thereof, optionally according to any preceding embodiment, comprising a phytoene content of 20 wt % of total carotenoids or greater.

In embodiment 26, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered Dunaliella alga, or extract thereof, optionally according to any preceding embodiment, comprising a phytoene content of 25 wt % of total carotenoids or greater.

30

25

In embodiment 27, the invention provides a Dunaliella alga, or extract thereof, or a powdered Dunaliella alga, or extract thereof; optionally according to any preceding embodiment, comprising a phytoene content of 30 wt % of total carotenoids or greater.

In embodiment 28, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered 35 Dunaliella alga, or extract thereof; optionally according to any preceding embodiment; comprising a phytoene content of 40 wt % of total carotenoids or greater.

In embodiment 29, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, comprising a phytoene content of 45 wt % of total carotenoids or greater.

5

10

15

20

25

For the avoidance of doubt, the content of total carotenoids will always total 100 wt%.

In embodiment 30, the invention provides a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment, wherein the *Dunaliella* alga is selected from *Dunaliella salina salina*, *Dunaliella salina bardawil* and *Dunaliella salina rubeus* (accession number CCAP 19/41).

In embodiment 31, the invention provides a composition comprising: a) a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment; and b) a pharmaceutically acceptable excipient.

In embodiment 32, the invention provides a process for the preparation of a *Dunaliella* alga comprising exposing the *Dunaliella* alga to light of wavelength 500-1000nm or 500 - 700nm or 700-1000nm; and/or eliminating light of wavelength less than 500nm (blue light). The process preferably produces a *Dunaliella* alga which has increased 9-cis  $\beta$ -carotene content; and/or an increased colourless carotenoid content, particularly an increased phytoene content; and/or an increased  $\alpha$ -carotene content.

In embodiment 33, the invention provides a process for the preparation of a *Dunaliella* alga comprising the steps:

- a) cultivating the *Dunaliella* alga under white light; and subsequently;
- b) exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm; and/or eliminating light of wavelength less than 500nm (blue light).

In embodiment 34, the invention provides a process according to embodiment 32 or 33, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm or 500-700nm or 700-1000nm; and/or eliminating light of wavelengths less than 500nm (blue light); has a duration sufficient to achieve an increase in the 9-*cis*: all trans ration of 20% or greater; preferably 100% or greater; more preferably 150% or greater.

35

30

In embodiment 35, the invention provides a process according to embodiments 32 to 34, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm or 500-700nm or 700-

WO 2019/097219

1000nm, preferably comprises the use of light of wavelength from greater than or equal to 500 to less than 830nm.

In embodiment 36, the invention provides a process according to embodiments 32 to 35, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm or 500-700nm or 700-1000nm, preferably comprises the use of light of wavelength 550-800nm.

In embodiment 37, the invention provides a process according to embodiments 32 to 36, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm or 500-700nm or 700-1000nm, preferably comprises the use of light of wavelength 600-750nm.

In embodiment 38, the invention provides a process according to embodiments 32 to 37, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm or 500-700nm or 700-1000nm, preferably comprises the use of light of wavelength 650-750nm.

15

35

10

In embodiment 39, the invention provides a process according to embodiments 32 to 36, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm or 500-700nm or 700-1000nm, preferably comprises the use of light of wavelength 600-700nm or 650-700nm.

- The process according to embodiments 32 to 39 may be used for the cultivation of any strains of *Dunaliella* that produce carotenoids; preferably the *Dunaliella* alga is selected from *Dunaliella* salina salina, *Dunaliella salina bardawil* and *Dunaliella salina rubeus* (accession number CCAP 19/41).
- In embodiment 40, the invention provides a process according to any one of embodiments 32 to 39, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm, preferably from greater than or equal to 500 to less than 830nm, preferably 550-800nm, more preferably 600-750nm, more preferably 650-750nm, and more preferably 600-700 or 650-700nm; and/or eliminating light of wavelength less than 500nm (blue light); has a duration at least 4 hours.

In embodiment 41, the invention provides a process according to any one of embodiments 32 to 40, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm, preferably from greater than or equal to 500 to less than 830nm, preferably 550-800nm, more preferably 600-750nm, more preferably 650-750nm, and more preferably 600-700 or 650-700nm; and/or eliminating light of wavelength less than 500nm (blue light); has a duration at least 12 hours.

WO 2019/097219

In embodiment 42, the invention provides a process according to any one of embodiments 32 to 41, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm, preferably from greater than or equal to 500 to less than 830nm, preferably 550-800nm, more preferably 600-750nm, more preferably 650-750nm, and more preferably 600-700 or 650-700nm; and/or eliminating light of wavelength less than 500nm (blue light); has a duration at least 24 hours.

PCT/GB2018/053278

In embodiment 43, the invention provides a process according to any one of embodiments 32 to 42, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm, preferably from greater than or equal to 500 to less than 830nm, preferably 550-800nm, more preferably 600-750nm, more preferably 650-750nm, and more preferably 600-700 or 650-700nm; and/or eliminating light of wavelength less than 500nm (blue light); has a duration at least 48 hours.

15

20

35

10

5

The cultivation step a) of embodiments 33 to 43 may comprise cultivating the *Dunaliella* alga using any suitable method, such as in open pond systems, including cascade raceways and conventional raceways; and in closed cultivation systems, including tubular, flat-panel, green wall and thin-layer photobioreactors (PBRs). The cultivation step a) of embodiments 33 to 43 may take place outdoors or indoors, including in greenhouses.

The white light used in step a) of embodiments 33 to 43 may be any suitable source of white light, including natural light and white LED light.

The light used in step b) of embodiments 32 to 43 may be any suitable source of light of the desired wavelength, such as use of a red LED light, far-red light, or infrared light; or the use of a red filter such as the commercially available filters 26 Bright red, 27 Medium Red and 787 Marius Red (available from LEE Filters); or use of a filter that eliminates blue light, such as the commercially available filters 105 Orange, 101 Yellow, or 010 Medium Yellow. Far red light sources are known in the horticultural field.

In embodiment 44, the invention provides a process according to any one of embodiments 33 to 43, wherein step a) comprises cultivating the *Dunaliella* alga under natural light for a period from the beginning of cultivation to at least the log growth phase; preferably to the early orange phase.

WO 2019/097219

In embodiment 45, the invention provides a process according to any one of embodiments 33 to 44, wherein in step b) the light has a wavelength in the range of from 650 nm to 700 nm and has an intensity of at least 10 µmol m<sup>-2</sup>s<sup>-1</sup>.

- In embodiment 46, the invention provides a process according to any one of embodiments 33 to 45 wherein in step b) the light of the desired wavelength is applied using a red filter; or using a red LED light, far-red light or infrared light; or using an orange or yellow filter which eliminates light of wavelength less than 500nm.
- In embodiment 47, the invention provides a process according to any one of embodiments 32 to 46, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm is carried out at a temperature of 20°C or less.
- In embodiment 48, the invention provides a process according to any one of embodiments 32 to 47, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm is carried out at a temperature of 15 °C or less.

In embodiment 49, the invention provides a process according to any one of embodiments 32 to 48, wherein the step of exposing the *Dunaliella* alga to light of wavelength 500-1000nm is carried out at a temperature of 12 °C or less.

In embodiment 50, the invention provides a process according to any one of embodiments 33 to 49, which comprises the additional steps:

- c) Harvesting the *Dunaliella* alga; and optionally
- d) Extracting the carotenoids.

20

25

In step c) of embodiment 50, the *Dunaliella* alga may be harvested by any suitable method; preferably using a centrifuge or membrane micro/ultrafiltration.

- In step d) of embodiment 50, the carotenoids may be extracted by any suitable process known to a person skilled in the art, such as extraction into a suitable organic solvent, or using supercritical CO<sub>2</sub>, or any of the methods described in Mäki-Arvela, *et al* (J. Chem. Technol. Biotechnol., 2014; 89: 1607–1626) or in Saini *et al* (Food Chemistry, 2018, 240, 90-103).
- In embodiment 51, the invention provides a process according to any one of embodiments 31 to 50, wherein the *Dunaliella* alga is selected from any *Dunaliella* strain that produces carotenoids;

preferably the *Dunaliella* alga is selected from *Dunaliella salina*, *Dunaliella salina* bardawil and *Dunaliella salina rubeus* (accession number CCAP 19/41).

In embodiment 52, the invention provides a process according to any one of embodiments 32 to 51, wherein in step a) the ambient temperature is in the range of from 4 °C to 45 °C. The skilled person will understand that the temperature may vary during the cultivation step a) within the range of summer day time temperatures of up to 45 °C and winter night time temperatures down to 4 °C.

- The inventors have further surprisingly found that production of the colourless carotenoids phytoene and phytofluene by a *Dunaliella* alga or extract thereof is increased through the application of a herbicide. Thus, in embodiment 53, the invention provides a process according to any one of embodiments 32 to 52, which process comprises the steps:
  - a) cultivating the *Dunaliella* alga under white light; subsequently;

5

15

25

30

35

- b) exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm; and/or eliminating light of wavelength less than 500nm (blue light); and
- c) applying a herbicide to the *Dunaliella* alga during step a) and/or step b).

For the avoidance of doubt, the term 'a herbicide' as used herein refers to a singular herbicide and to combinations of herbicides. When combinations of herbicides are used in the present invention, the herbicides may be applied simultaneously or sequentially.

Phytoene desaturase inhibitors, such as norflurazon, diflufenican and picolinafen, are known to have an effect on the accumulation of phytoene in *Dunaliella* alga. By inhibiting the activity of the phytoene desaturase (PDS), the carotenoid pathway is interrupted and the transformation of phytoene into other carotenoids is reduced. The inventors have now surprisingly found that phytoene and phytofluene content in *Dunaliella* alga can also be increased by treating the *Dunaliella* alga by application of a herbicide which is a cell division and phytochrome inhibitor, such as Chlorpropham, and postulate that such herbicides act by modulation of phytoene synthase, that is, by increasing the production of phytoene and phytofluene in the carotenoid pathway rather than by reducing the transformation of phytoene as has been seen with the application of a PDS inhibitor herbicide.

In addition to phytoene desaturase inhibitors, suitable herbicides for use in the present invention include those listed in the table below.

Mode of	Site of action	Active ingredient
action (effect	and WSSA	(IUPAC name; CAS number)
on plant	group*	(101716 name, Crus number)
growth)	group	
AMINO ACID	ALS	Amidosulfuron
SYNTHESIS	INHIBITORS	(1-(4,6-dimethoxypyrimidin-2-yl)-3-
INHIBITORS	(acetolactate	[methyl(methylsulfonyl)sulfamoyl]urea; 120923-37-7
	synthase)	Azimsulfuron
	Group 2	1-(4,6-dimethoxypyrimidin-2-yl)-3-[2-methyl-4-(2-
	_	methyltetrazol-5-yl)pyrazol-3-yl]sulfonylurea; 120162-
		55-2
		bensulfuron-methyl
		methyl 2-[(4,6-dimethoxypyrimidin-2-
		yl)carbamoylsulfamoylmethyl]benzoate; 83055-99-6
		chlorimuron-ethyl
		ethyl 2-[(4-chloro-6-methoxypyrimidin-2-
		yl)carbamoylsulfamoyl]benzoate; 90982-32-4
		chlorsulfuron
		1-(2-chlorophenyl)sulfonyl-3-(4-methoxy-6-methyl-1,3,5-
		triazin-2-yl)urea; 64902-72-3
		cinosulfuron
		1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-3-[2-(2-methoxyethoxy)phenyl]sulfonylureacyclosulfamuron;
		94593-91-6
		ethametsulfuron-methyl
		methyl 2-[[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-
		yl]carbamoylsulfamoyl]benzoate; 97780-06-8
		ethoxysulfuron
		(2-ethoxyphenyl) N-[(4,6-dimethoxypyrimidin-2-
		yl)carbamoyl]sulfamate; 126801-58-9
		flazasulfuron
		1-(4,6-dimethoxypyrimidin-2-yl)-3-[3-
		(trifluoromethyl)pyridin-2-yl]sulfonylurea; 104040-78-0
		flupyrsulfuron-methyl-sodium
		sodium;(4,6-dimethoxypyrimidin-2-yl)-[[3-
		methoxycarbonyl-6-(trifluoromethyl)pyridin-2-
		yl]sulfonylcarbamoyl]azanide; 144740-54-5
		foramsulfuron
		2-[(4,6-dimethoxypyrimidin-2-yl)carbamoylsulfamoyl]-4-
		formamido-N,N-dimethylbenzamide; 173159-57-4 halosulfuron-methyl
		methyl 3-chloro-5-[(4,6-dimethoxypyrimidin-2-
		yl)carbamovlsulfamoyl]-1-methylpyrazole-4-carboxylate;
		100784-20-1
		imazosulfuron
		1-(2-chloroimidazo[1,2-a]pyridin-3-yl)sulfonyl-3-(4,6-
		dimethoxypyrimidin-2-yl)urea; 122548-33-8
		iodosulfuron
		4-iodo-2-[(4-methoxy-6-methyl-1,3,5-triazin-2-
		yl)carbamoylsulfamoyl]benzoic acid
		mesosulfuron
		2-[(4,6-dimethoxypyrimidin-2-yl)carbamoylsulfamoyl]-4-
		(methanesulfonamidomethyl)benzoic acid; 400852-66-6
		metsulfuron-methyl

methyl 2-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoylsulfamoyl]benzoate; 74223-64-6 nicosulfuron

2-[(4,6-dimethoxypyrimidin-2-yl)carbamoylsulfamoyl]-N,N-dimethylpyridine-3-carboxamide; 111991-09-4

### oxasulfuron

oxetan-3-yl 2-[(4,6-dimethylpyrimidin-2-yl)carbamoylsulfamoyl]benzoate; 144651-06-9

# primisulfuron-methyl

methyl 2-[[4,6-bis(difluoromethoxy)pyrimidin-2-yl]carbamoylsulfamoyl]benzoate; 86209-51-0

# prosulfuron

1-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-3-[2-(3,3,3-trifluoropropyl)phenyl]sulfonylurea; 94125-34-5

# pyrazosulfuron-ethyl

ethyl 5-[(4,6-dimethoxypyrimidin-2-yl)carbamoylsulfamoyl]-1-methylpyrazole-4-carboxylate; 93697-74-6

#### rimsulfuron

1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-

ethylsulfonylpyridin-2-yl)sulfonylurea; 122931-48-0

## sulfometuron-methyl

methyl 2-[(4,6-dimethylpyrimidin-2-

yl)carbamoylsulfamoyl]benzoate; 74222-97-2

## sulfosulfuron

1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea; 141776-32-1

# thifensulfuron-methyl

methyl 3-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoylsulfamoyl]thiophene-2-carboxylate; 79277-27-3

#### triasulfuron

1-[2-(2-chloroethoxy)phenyl]sulfonyl-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)urea; 82097-50-5

## tribenuron-methyl

methyl 2-[[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-methylcarbamoyl]sulfamoyl]benzoate; 101200-48-0

#### trifloxysulfuron

1-(4,6-dimethoxypyrimidin-2-yl)-3-[3-(2,2,2-

trifluoroethoxy)pyridin-2-yl]sulfonylurea; 145099-21-4

#### triflusulfuron-methyl

methyl 2-[[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoylsulfamoyl]-3-methylbenzoate; 126535-15-7

## tritosulfuron

1-[4-methoxy-6-(trifluoromethyl)-1,3,5-triazin-2-yl]-3-[2-(trifluoromethyl)phenyl]sulfonylurea; 142469-14-5 imazapic

5-methyl-2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)pyridine-3-carboxylic acid; 104098-48-8

# imazamethabenz-methyl

methyl 4-methyl-2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)benzoate; 69969-22-8

# imazamox

5-(methoxymethyl)-2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)pyridine-3-carboxylic acid; 114311-32-9

# imazapyr

2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)pyridine-3-carboxylic acid; 81334-34-1

#### imazaquin

2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)quinoline-3-carboxylic acid; 81335-46-8

#### **Imazethapyr**

5-ethyl-2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)pyridine-3-carboxylic acid; 81335-77-5

#### cloransulam-methyl

methyl 3-chloro-2-[(5-ethoxy-7-fluoro-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)sulfonylamino]benzoate; 147150-35-4

## diclosulam

N-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide; 145701-21-9

#### florasulam

N-(2,6-difluorophenyl)-8-fluoro-5-methoxy-[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide; 145701-23-1

#### flumetsulam

N-(2,6-difluorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide; 98967-40-9

#### metosulam

N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy-[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide; 139528-85-1

# penoxsulam

2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-

(trifluoromethyl)benzenesulfonamide; 219714-96-2

#### bispyribac-sodium

sodium;2,6-bis[(4,6-dimethoxypyrimidin-2-yl)oxy]benzoate; 125401-92-5

# pyribenzoxim

(benzhydrylideneamino) 2,6-bis[(4,6-

dimethoxypyrimidin-2-yl)oxy]benzoate; 168088-61-7

## pyriftalid

7-(4,6-dimethoxypyrimidin-2-yl)sulfanyl-3-methyl-3H-2-benzofuran-1-one; 135186-78-6

# pyrithiobac-sodium

sodium;2-chloro-6-(4,6-dimethoxypyrimidin-2-vl)sulfanylbenzoate; 123343-16-8

# pyriminobac-methyl

methyl 2-(4,6-dimethoxypyrimidin-2-yl)oxy-6-[(E)-N-methoxy-C-methylcarbonimidoyl]benzoate; 136191-64-5

# flucarbazone-sodium

sodium;(3-methoxy-4-methyl-5-oxo-1,2,4-triazole-1-carbonyl)-[2-(trifluoromethoxy)phenyl]sulfonylazanide; 181274-17-9

# propoxycarbazone-sodium

		sodium;(2-methoxycarbonylphenyl)sulfonyl-(4-methyl-5-
		oxo-3-propoxy-1,2,4-triazole-1-carbonyl)azanide; 181274-15-7
	EPSP SYNTHASE	glyphosate 2-(phosphonomethylamino)acetic acid; 1071-83-6
	INHIBITOR	sulfosate (glyphosate-trimesium)
	(5- enolpyruvyl-	2-(phosphonomethylamino)acetate;trimethylsulfanium; 81591-81-3
	shikimate3-	81391-61-3
	phosphate)	
GROWTH	Group 9 TIR1 AUXIN	Clomeprop
REGULATOR S	RECEPTORS (synthetic	2-(2,4-dichloro-3-methylphenoxy)-N-phenylpropanamide; 84496-56-0
	auxins)	2,4-D
	Group 4	2-(2,4-dichlorophenoxy)acetic acid; 94-75-7 2,4-DB
		4-(2,4-dichlorophenoxy)butanoic acid;N-
		methylmethanamine; 2758-42-1 dichlorprop (2,4-DP)
		2-(2,4-dichlorophenoxy)propanoic acid; 120-36-5  MCPA
		2-(4-chloro-2-methylphenoxy)acetic acid; 94-74-6 MCPB
		4-(4-chloro-2-methylphenoxy)butanoic acid; 94-81-5 mecoprop (MCPP or CMPP)
		2-(4-chloro-2-methylphenoxy)propanoic acid; 93-65-2
		chloramben 3-amino-2,5-dichlorobenzoic acid; 133-90-4
		dicamba
		3,6-dichloro-2-methoxybenzoic acid; 1918-00-9 thiobarbituric acid (TBA)
		2-sulfanylidene-1,3-diazinane-4,6-dione; 504-17-6
		clopyralid
		3,6-dichloropyridine-2-carboxylic acid; 1702-17-6 <b>fluroxypyr</b>
		2-(4-amino-3,5-dichloro-6-fluoropyridin-2-yl)oxyacetic acid; 69377-81-7
		picloram 4-amino-3,5,6-trichloropyridine-2-carboxylic acid; 1918-
		02-1 triclopyr
		2-(3,5,6-trichloropyridin-2-yl)oxyacetic acid; 55335-06-3
		quinclorac (also HRAC group L) 3,7-dichloroquinoline-8-carboxylic acid; 84087-01-4
		quinmerac 7-chloro-3-methylquinoline-8-carboxylic acid; 90717-03-
		benazolin-ethyl
		ethyl 2-(4-chloro-2-oxo-1,3-benzothiazol-3-yl)acetate; 25059-80-7
	AUXIN TRANSPORT	naptalam 2-(naphthalen-1-ylcarbamoyl)benzoic acid; 132-66-1
	INHIBITOR	diflufenzopyr-sodium

	0 10	1: 2 ((D) NI ((2.5 1) 0
	Group 19	sodium;2-[(E)-N-[(3,5-difluorophenyl)carbamoylamino]- C-methylcarbonimidoyl]pyridine-3-carboxylate; 109293- 98-3
NITROGEN	GLUTAMINE	glufosinate-ammonium
	SYNTHETAS	
METABOLIS		2-amino-4-[hydroxy(methyl)phosphoryl]butanoic
M	E INHIBITOR	acid;azane; 77182-82-2
INHIBITOR	Group 10	bialaphos (bilanaphos)
		(2S)-2-[[(2S)-2-amino-4-
		[hydroxy(methyl)phosphoryl]butanoyl]amino]propanoyl]a
		mino propanoic acid;
DICMENT	DILVTOENE	
PIGMENT	PHYTOENE	norflurazon
INHIBITORS	DESATURAS	4-chloro-5-(methylamino)-2-[3-
	E (PDS)	(trifluoromethyl)phenyl]pyridazin-3-one; 27314-13-2
	INHIBITOR	diflufenican
	Group 12	N-(2,4-difluorophenyl)-2-[3-
	Croup 12	(trifluoromethyl)phenoxy pyridine-3-carboxamide;
		83164-33-4
		picolinafen
		N-(4-fluorophenyl)-6-[3-
		(trifluoromethyl)phenoxy]pyridine-2-carboxamide;
		137641-05-5
		beflubutamid
		N-benzyl-2-[4-fluoro-3-
		(trifluoromethyl)phenoxy]butanamide; 113614-08-7
		fluridone
		1-methyl-3-phenyl-5-[3-(trifluoromethyl)phenyl]pyridin-
		4-one; 59756-60-4
		flurochloridone
		3-chloro-4-(chloromethyl)-1-[3-
		(trifluoromethyl)phenyl]pyrrolidin-2-one; 61213-25-0
		flurtamone
		5-(methylamino)-2-phenyl-4-[3-
		(trifluoromethyl)phenyl]furan-3-one; 96525-23-4
	Bleaching	mesotrione
	HPPD	2-(4-methylsulfonyl-2-nitrobenzoyl)cyclohexane-1,3-
	INHIBITORS	dione; 104206-82-8
	Group 27	sulcotrione
	Group 21	
		2-(2-chloro-4-methylsulfonylbenzoyl)cyclohexane-1,3-
		dione; 114680-61-4
		isoxachlortole
		(4-chloro-2-methylsulfonylphenyl)-(5-cyclopropyl-1,2-
		oxazol-4-yl)methanone; 141112-06-3
		isoxaflutole
		(5-cyclopropyl-1,2-oxazol-4-yl)-[2-methylsulfonyl-4-
		(trifluoromethyl)phenyl]methanone; 141112-29-0
		benzofenap
		2-[4-(2,4-dichloro-3-methylbenzoyl)-2,5-dimethylpyrazol-
		3-yl]oxy-1-(4-methylphenyl)ethenone; 82692-44-2
		pyrazolynate
		1
		[4-(2,4-dichlorobenzoyl)-2,5-dimethylpyrazol-3-yl] 4-
		methylbenzenesulfonate; 58011-68-0
		pyrazoxyfen
		2-[4-(2,4-dichlorobenzoyl)-2,5-dimethylpyrazol-3-yl]oxy-
		1-phenylethanone; 71561-11-0
	1	1 - F

		benzobicyclon
		3-(2-chloro-4-methylsulfonylbenzoyl)-2-
		phenylsulfanylbicyclo[3.2.1]oct-2-en-4-one; 156963-66-5
		bromobutide
		2-bromo-3,3-dimethyl-N-(2-phenylpropan-2-
		yl)butanamide; 74712-19-9
		(chloro)-flurenol
		2-chloro-9-hydroxyfluorene-9-carboxylic acid; 2464-37-1
		cinmethylin
		1-methyl-2-[(2-methylphenyl)methoxy]-4-propan-2-yl-7-
		oxabicyclo[2.2.1]heptane; 87818-31-3
		cumyluron
		1-[(2-chlorophenyl)methyl]-3-(2-phenylpropan-2-yl)urea;
		99485-76-4
		dazomet
		3,5-dimethyl-1,3,5-thiadiazinane-2-thione; 533-74-4
		dymron (daimuron)
		1-(4-methylphenyl)-3-(2-phenylpropan-2-yl)urea; 42609-
		52-9
		methyl-dymron (methyl-dimuron)
		1-methyl-1-phenyl-3-(2-phenylpropan-2-yl)urea; 42609-
		73-4
		etobenzanid
		N-(2,3-dichlorophenyl)-4-(ethoxymethoxy)benzamide;
		79540-50-4
		fosamine
		carbamoyl(ethoxy)phosphinic acid; 59682-52-9
		indanofan
		2-[[2-(3-chlorophenyl)oxiran-2-yl]methyl]-2-ethylindene-
		1,3-dione; 133220-30-1
		metam
		methylcarbamodithioic acid; 144-54-7
		oxaziclomefone
		3-[2-(3,5-dichlorophenyl)propan-2-yl]-6-methyl-5-
		phenyl-2H-1,3-oxazin-4-one; 153197-14-9
		oleic acid
		(Z)-octadec-9-enoic acid; 112-80-1
		pelargonic acid
		nonanoic acid; 112-05-0
		pyributicarb
		O-(3-tert-butylphenyl) N-(6-methoxypyridin-2-yl)-N-
		methylcarbamothioate; 88678-67-5
	Inhibition of	amitrole
	carotenoid	(in vivo inhibition of
	biosynthesis	lycopene cyclase)
	(unknown	1H-1,2,4-triazol-5-amine; 61-82-5
	target)	
	Group 11	
SEEDLING	MICROTUBU	benefin (benfluralin)
ROOT	LE	N-butyl-N-ethyl-2,6-dinitro-4-(trifluoromethyl)aniline;
GROWTH	INHIBITORS	1861-40-1
INHIBITORS	Group 3	butralin
		N-butan-2-yl-4-tert-butyl-2,6-dinitroaniline, 33629-47-9
		dinitramine

	T	
		3-N,3-N-diethyl-2,4-dinitro-6-(trifluoromethyl)benzene- 1,3-diamine; 29091-05-2 ethalfluralin
		N-ethyl-N-(2-methylprop-2-enyl)-2,6-dinitro-4- (trifluoromethyl)aniline; 55283-68-6
		oryzalin 4-(dipropylamino)-3,5-dinitrobenzenesulfonamide;
		19044-88-3
		pendimethalin 3,4-dimethyl-2,6-dinitro-N-pentan-3-ylaniline; 40487-42-
		trifluralin
		2,6-dinitro-N,N-dipropyl-4-(trifluoromethyl)aniline; 1582-09-8
		amiprophos-methyl N-[methoxy-(4-methyl-2-
		nitrophenoxy)phosphinothioyl]propan-2-amine; 36001-88-4
		butamiphos
		N-[ethoxy-(5-methyl-2-
		nitrophenoxy)phosphinothioyl]butan-2-amine; 36335-67-
		dithiopyr
		3-S,5-S-dimethyl 2-(difluoromethyl)-4-(2-methylpropyl)-6-(trifluoromethyl)pyridine-3,5-dicarbothioate; 97886-45-
		8
		thiazopyr methyl 2-(difluoromethyl)-5-(4,5-dihydro-1,3-thiazol-2-
		yl)-4-(2-methylpropyl)-6-(trifluoromethyl)pyridine-3- carboxylate; 117718-60-2
		propyzamide (pronamide)
		propenamide; 79-05-0 tebutam
		N-benzyl-2,2-dimethyl-N-propan-2-ylpropanamide; 35256-85-0
		DCPA (chlorthal-dimethyl)
		dimethyl 2,3,5,6-tetrachlorobenzene-1,4-dicarboxylate; 1861-32-1
SEEDLING SHOOT	LONG- CHAIN	acetochlor 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-
GROWTH	FATTY ACID	methylphenyl)acetamide; 34256-82-1
INHIBITORS	INHIBITORS	alachlor
	(inhibition of cell division)	2-chloro-N-(2,6-diethylphenyl)-N- (methoxymethyl)acetamide; 15972-60-8
	Group15	butachlor
		N-(butoxymethyl)-2-chloro-N-(2,6-
		diethylphenyl)acetamide; 23184-66-9 dimethachlor
		2-chloro-N-(2,6-dimethylphenyl)-N-(2-methoxyethyl)acetamide; 50563-36-5
		dimethenamid
		2-Chloro- <i>N</i> -(2,4-dimethyl-3-thienyl)- <i>N</i> -(2-methoxy-1-methylethyl)acetamide;
		metazachlor

2-chloro-N-(2,6-dimethylphenyl)-N-(pyrazol-1-ylmethyl)acetamide; 67129-08-2   metolachlor   2-chloro-N-(2-ethyl-6-methylphenyl)-N-(1-methoxypropan-2-ylacetamide; 51218-45-2   pethoxamid   2-chloro-N-(2-dehoxyethyl)-N-(2-methyl-1-phenylprop-1-enylacetamide; 106700-29-2   pretilachlor   2-chloro-N-(2,6-diethylphenyl)-N-(2-propoxyethyl)acetamide; 51218-49-6   propachlor   2-chloro-N-(2,6-diethylphenyl)-N-(2-propoxyethyl)acetamide; 51218-49-6   propachlor   2-chloro-N-(2,6-diethylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5   thenylchlor   2-chloro-N-(2,6-dimethylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5   thenylchlor   2-chloro-N-(2,6-dimethylphenyl)-N-(3-methoxythiophen-2-yl)methyllacetamide; 96491-05-3   diphenamid   N,N-dimethyl-2,2-diphenylacetamide; 96491-05-3   diphenamid   N,N-dimethyl-2,2-diphenylacetamide; 957-51-7   napropamide   N,N-diethyl-2-aphthalen-1-yloxypropanamide; 15299-99-7   naproanilide   2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8   flufenacet   N-(4-fluorophenyl)-N-propan-2-yl-2-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yi]oxylacetamide; 142359-58-3   mefenacet   2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 37250-68-7   fentrazamide   4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 15237-07-1   anilofos   N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 2459-01-0   cafenstrole   N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 152306-83-4   piperophos   2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)cthenone; 24151-93-7   dichlobenil   propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3   propham   propan-2-yl N-phenylcarbamate; 122-42-9   carbetamide   delamide   delamide   delamide   delamide   dichlorophenyl-pan-2-dipropan-2-yl N-phenylcarbamate; 122-42-9   carbetamide   delamide   delamide   delamide   delamide   delam			
metolachlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(1- methoxypropan-2-yl)acetamide; 51218-45-2 pethoxamid 2-chloro-N-(2-ethoxyethyl)-N-(2-methyl-1-phenylprop-1- enyl)acetamide; 106700-29-2 prefilachlor 2-chloro-N-(2,6-diethylphenyl)-N-(2- propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-(2,6-diethylphenyl)-N-(propan-2- yloxymethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2- yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-(propan-2- yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-(3- methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 metenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 12306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 thylpiperidin-1-yl)ethenone; 24151-93-7 methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 thylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 thy			
2-chloro-N-(2-ethyl-6-methylphenyl)-N-(1-methysypopan-2-ylbacetamide, 51218-45-2   pethoxamid   2-chloro-N-(2-ethoxyethyl)-N-(2-methyl-1-phenylprop-1-enylpacetamide; 106700-29-2   pretilactlor   2-chloro-N-(2,6-diethylphenyl)-N-(2-propoxyethylpacetamide; 51218-49-6   propachlor   2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7   propisochlor   2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5   thenylchlor   2-chloro-N-(2-dihyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5   thenylchlor   2-chloro-N-(2,6-dimethylphenyl)-N-(1-amethyl)-1-aphthalen-1-yloxypropanamide; 15290-10-2-dimethylphenyl-2-aphthalen-1-yloxypropanamide; 15290-10-7   napropamide   N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15290-10-7   napropamide   N,N-diethyl-2-naphthalen-2-yloxy-N-phenylpropanamide; 15290-10-7   napropamide   N,N-diethyl-2-naphthalen-2-yloxy-N-phenylpropanamide; 15290-10-7   napropamide   N-d-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yloxy]-N-methyl-N-phenylacetamide; 142459-58-3   mefenacet   N-d-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yloxy]-N-methyl-N-phenylacetamide; 158237-07-1   anilofos   N-d-chlorophenyl)-N-propan-2-ylacetamide; 158237-07-1   anilofos   N-d-chlorophenyl-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 127306-83-4   piperophos   2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7   dichlobeni   0-f CELL   WALL   SYNTHESIS   SYNTH			
methoxypropan-2-yl)acetamide; 51218-45-2 pethoxamid 2-chloro-N-(2-ethoxyethyl)-N-(2-methyl-1-phenylprop-1- enylacetamide; 106700-29-2 pretilachlor 2-chloro-N-(2,6-diethylphenyl)-N-(2- propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2- yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3- methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamilde N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenii 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4 TNHIBITION OF MITOSIS MICROTUBU LE UN-phenylearbamate; 101-21-3 propham propan-2-yl N-phenylearbamate; 101-21-3 propham propan-2-yl N-phenylearbamate; 122-42-9			
pethoxamid 2-chloro-N-(2-cthoxyethyl)-N-(2-methyl-1-phenylprop-1-enyl)acetamide; 106700-29-2 pretilachlor 2-chloro-N-(2,6-diethylphenyl)-N-(2-propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2-cthyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 25506-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidim-1-yl)ethenone; 24151-93-7 dichlobenil 0-f CELL WALL SYNTHESIS SYNTHESIS SYNTHESIS Group 20 INHIBITION OF GELL WALL SYNTHESIS MICROTUBU LE  Chlorthiamide LE Chlorthiamide 2-chlorophenyl-carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
2-chloro-N-(2-cthoxyethyl)-N-(2-methyl-1-phenylprop-1-enyl)acetamide; 106700-29-2 pretilachlor 2-chloro-N-(2,6-diethylphenyl)-N-(2-propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2,6-dimethylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-(3-methoxythiophen-2-ylomethyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproaniide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-ylloxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-(2-methylphenyl)sulfonyl-1-2-dipropoxyphosphinothioylsulfanyl-1-2-dipropoxyphos			
enyl)acetamide; 106700-29-2 pretilachlor 2-chloro-N-(2,6-diethylphenyl)-N-(2- propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-(2-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2- yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-(3- methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4 chlortopham propan-2-yl N-phenylcarbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			•
pretiachlor 2-chloro-N-(2,6-diethylphenyl)-N-(2-propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE Chlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonecarbothioamide; 1918-13-4 propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
2-chloro-N-(2,6-diethylphenyl)-N-(2-propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2-cthyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yloxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-ehlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1 (2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 0F CELL WALL SYNTHESIS SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  Chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			enyl)acetamide; 106700-29-2
propoxyethyl)acetamide; 51218-49-6 propachlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2-ethyl-6-methyl)phenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 0F CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU MICROTUBU LE  chloroperacyl N-gacetamide; 122-42-9 nropana-2-yl N-gacetamide; 122-42-9			pretilachlor
propachlor 2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl)oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzencarbothioamide; 1918-13-4  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU MICROTUBU MICROTUBU LE  Chlorophenyl)-arbamate; 101-21-3 propham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			2-chloro-N-(2,6-diethylphenyl)-N-(2-
2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7 propisochlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2- yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3- methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-cthyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobeni C			propoxyethyl)acetamide; 51218-49-6
propisochlor 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonecarbothioamide; 1918-13-4  Chlorropham propan-2-yl N-ga-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
2-chloro-N-(2-ethyl-6-methylphenyl)-N-(propan-2-yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  Chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  Chlorpopham propan-2-yl N-phenylcarbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			2-chloro-N-phenyl-N-propan-2-ylacetamide; 1918-16-7
yloxymethyl)acetamide; 86763-47-5 thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  NHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  Vlocky Adams of the methoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7  chloropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 102-24-9			propisochlor
thenylchlor 2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yloxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonecarbothioamide; 1918-13-4  TNHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  Chlorpopham propan-2-yl N-phenylcarbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
2-chloro-N-(2,6-dimethylphenyl)-N-[(3-methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299-99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  12-chlorobenzenecarbothioamide; 1918-13-4  chlorthiamide 2-naphthalen-1-yloxypropanamic, 101-21-3 propham propan-2-yl N-phenylcarbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			yloxymethyl)acetamide; 86763-47-5
methoxythiophen-2-yl)methyl]acetamide; 96491-05-3 diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  methylpiperidin-1-yl-dehenone; 24151-93-7  dichlorbeni chlorthiamide 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-ghenylcarbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			thenylchlor
diphenamid N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-eyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 0F CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  dipperopham propan-2-yl N-dichlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			2-chloro-N-(2,6-dimethylphenyl)-N-[(3-
N,N-dimethyl-2,2-diphenylacetamide; 957-51-7 napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlorbenil 2,6-dichlorobenzenetarbothioamide; 1918-13-4 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4 chlorthiamide LE chlortpopham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
napropamide N,N-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4 Chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
N,Ñ-diethyl-2-naphthalen-1-yloxypropanamide; 15299- 99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-N- phenylacetamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2-diethyl-3-q-vlacetamide; 158-330-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonecarbothioamide; 1918-13-4 Chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
99-7 naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonecarbothioamide; 1918-13-4 Chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			• •
naproanilide 2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzonitrile; 1198-13-4  Chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
2-naphthalen-2-yloxy-N-phenylpropanamide; 52570-16-8 flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  Chlorpopham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			99-7
flufenacet N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
N-(4-fluorophenyl)-N-propan-2-yl-2-[[5- (trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N- phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  N-(4-fluorophenyl)-N-propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy]acetamide; 142459-58-3 mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  (trifluoromethyl)-1,3,4-thiadiazol-2-yll]oxylendinge; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- 1-(2-defensional) (2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7 INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  chloropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
142459-58-3   mefenacet   2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7   fentrazamide   4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1   anilofos   N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0   cafenstrole   N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4   piperophos   2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7   INHIBITION   OF CELL   WALL   SYNTHESIS   SYNTHESIS   Group 20   INHIBITION   OF MITOSIS   MICROTUBU   LE   Chloropham   propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3   propham   propan-2-yl N-phenylcarbamate; 122-42-9			
mefenacet 2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7 INHIBITION OF CELL WALL SYNTHESIS SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  Chlorpopham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  2-(1,3-benzothiazol-2-yloxy)-N-methyl-N-phenyl-N-methyl-N-phenyl-soxotetrazole-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-1-(0-cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7  chlorbenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  phenylacetamide; 73250-68-7 fentrazamide 4-(2-chlorophenyl)-sovethio-1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylophenone; 24151-93-7 dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  fentrazamide 4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)sulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  4-(2-chlorophenyl)-N-cyclohexyl-N-ethyl-5-oxotetrazole- 1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)sulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  1-carboxamide; 158237-07-1 anilofos N-(4-chlorophenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlorobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
anilofos N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl- N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  Chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  N-(4-chlorophenyl)-2-dimethoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
N-propan-2-ylacetamide; 64249-01-0 cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  N-propan-2-yl N-ghenylcarbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  cafenstrole N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  N,N-diethyl-3-(2,4,6-trimethylphenyl)sulfonyl-1,2,4- triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  triazole-1-carboxamide; 125306-83-4 piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  piperophos 2-dipropoxyphosphinothioylsulfanyl-1-(2- methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7  INHIBITION OF CELL OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  2-dipropoxyphosphinothioylsulfanyl-1-(2-methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			l
INHIBITION OF CELL OF CELL 2,6-dichlorobenzonitrile; 1194-65-6 WALL WALL SYNTHESIS Group 20 INHIBITION OF MITOSIS MICROTUBU LE  methylpiperidin-1-yl)ethenone; 24151-93-7  dichlobenil 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
INHIBITION OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  OF CELL 2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4 chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
OF CELL WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  2,6-dichlorobenzonitrile; 1194-65-6 chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4 chloropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
WALL SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  WALL SYNTHESIS Chlorthiamide 2,6-dichlorobenzenecarbothioamide; 1918-13-4  Chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
SYNTHESIS Group 20  INHIBITION OF MITOSIS MICROTUBU LE  2,6-dichlorobenzenecarbothioamide; 1918-13-4  chlorpropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3  propham propan-2-yl N-phenylcarbamate; 122-42-9			
INHIBITION OF MITOSIS OF MITOSIS MICROTUBU LE Chloropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9			
INHIBITION OF MITOSIS OF MITOSIS MICROTUBU LE Chloropham propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9	SYNTHESIS		2,6-dichlorobenzenecarbothioamide; 1918-13-4
OF MITOSIS MICROTUBU MICROTUBU LE propan-2-yl N-(3-chlorophenyl)carbamate; 101-21-3 propham propan-2-yl N-phenylcarbamate; 122-42-9	Datas	*	
MICROTUBU Dropham propan-2-yl N-phenylcarbamate; 122-42-9			
LE propan-2-yl N-phenylcarbamate; 122-42-9			
			<del>*                                   </del>
carbetamide	LE	LE	
			carbetamide

ORGANISAT	ORGANISAT	[(2R)-1-(ethylamino)-1-oxopropan-2-yl] N-
ION	ION	phenylcarbamate; 16118-49-3
	Group 23	
UNKNOWN	Group 25	arylaminopropionic acid
	_	3-(prop-2-enylamino)propanoic acid;
UNKNOWN	Group 26	quinoline carboxylic acid
		chlorocarbonic-acid
		carbonochloridic acid; 463-73-0
		pyrazolium
		1H-pyrazol-2-ium;
UNKNOWN	Group 16	benzofurane

<sup>\*</sup>site of action groups designated by the WSSA (Weed Science Society of America)

The active herbicidal ingredients listed above may be used as a free acid or base, or as a suitable salt. Where the compound possesses a chiral centre, the racemic form or a specific diasteroisomer or enantiomer may be used.

#### Particular suitable herbicides include:

5

10

15

20

25

Norflurazon [4-chloro-5-methylamino-2-(3-trifluoromethylphenyl)-pyridazin-3(2H)one] is a pyridazinone bleaching herbicide which inhibits carotene biosynthesis in photosynthetic organisms including D. salina, by binding reversibly in a non-competitive manner with its target enzyme phytoene desaturase. In Dunaliella sp it causes the accumulation of phytoene (Ben-Amotz A, Gressel J, Avron M (1987) Massive accumulation of phytoene induced by norflurazon in Dunaliella bardawil (Chlorophyceae) prevents recovery from photoinhibition. J Phycol 23:176-181), but not phytofluene (Ben-Amotz A, Lers A, Avron M (1988) Stereoisomers of beta carotene and phytoene in the alga Dunaliella bardawil. Plant Physiol 86:1286–1291). Other known phytoene desaturase (PDS) inhibitor herbicides, such as diflufenican and picolinafen, will also therefore permit phytoene accumulation and are suitable for use in the present invention. Chlorpropham (isopropyl N-(3-chlorophenyl) carbamate (CIPC) (commercial names: Bud Nip, Taterpex, Preventol, Elbanil, Metoxon, Nexoval, Stickman Pistols, Preweed, Furloe, Stopgerme-S, Sprout Nip, Mirvale, Bygran, ChlorIPC, CHLOROPROPHAM, Spud-Nic, Spud-Nie, Chloro-IFK, Chloro-IPC, Keim-stop, Triherbicide CIPC) is a carbamate herbicide and plant growth regulator used for pre-emergence control of grass weeds in alfalfa, lima and snap beans, blueberries, cranberries, carrots, cranberries, ladino clover, garlic, seed grass, onions, spinach, sugar beets, tomatoes, safflower, soybeans, gladioli and woody nursery stock. In the post-harvest treatment of potatoes during storage and transport, it is also used as a sprout suppressant and for sucker control in tobacco. It is considered to be a phytochrome inhibitor (Mann et al 1967 Nature 213, 420-421), and in wheat, has been shown to disorganize cell microtubules and microtubule organizing centres to prevent cell division (Eleftheriou, E. & Bekiari, E. Plant and Soil (2000) 226: 11. Ultrastructural effects of the herbicide chlorpropham (CIPC) in root tip cells of wheat).

WO 2019/097219 PCT/GB2018/053278

Aminopyralid (4-amino-3, 6-dichloropyridine-2-carboxylic acid) is a post-emergent, auxin-type herbicide that inhibits cell division and has been widely used for weed control. It is a member of the pyridine carboxylic acid family and induces an auxin-type response in susceptible plant species, causing epinastic bending and twisting of the stems that result in growth inhibition. (Li, W., et al (2018), Ecotoxicology and Environmental Safety, 155, 17-25).

**Carbetamide** ((*R*)-1-(ethylcarbamoyl)ethyl carbanilate) is a pre- and post-emergence herbicide which targets microtubuleorganizing centres and disrupts mitosis and cytokinesis in proliferating plant tissues, inhibiting cell division (Giménez-Abián, M.I., Panzera, F., López-Sáez, J.F. et al. Protoplasma (1998) 204: 119).

10 **Chlorsulfuron** is a sulfonylurea herbicide which inhibits plant acetohydroxyacid synthase, the first enzyme in the branched-chain amino acid biosynthesis pathway and is closely associated with an inhibition of plant cell division.

Glyphosate acts as a transition state inhibitor of 5-enolpyruvylshikimate-3-phosphate synthase which is responsible for facilitating the assembly of shikimate-3-phosphate and phosphoenylpyruvate in the shikimate pathway and is a critical biosynthetic pathway in plant cellular plastids. (d'Avignon, Ge, (2018) J. Magnetic Resonance, 292, 59-72). It is also linked to phytochrome inhibition (Duke et al (1979), Effects of Glyphosate on Metabolism of Phenolic Compounds. Physiologia Plantarum, 46: 307-317).

In embodiment 54, the invention provides a process according to embodiment 53, wherein the herbicide is selected from amino acid synthesis inhibitors, growth regulators, nitrogen metabolism inhibitors, pigment inhibitors, seedling root growth inhibitors, seedling shoot growth inhibitors, cell wall synthesis inhibitors, mitosis microtubule organisation inhibitors, and combinations thereof.

25

30

15

In embodiment 55, the invention provides a process according to embodiment 53 or 54, wherein the herbicide is selected from acetolactate synthase (ALS) inhibitors, 5-enolpyruvyl-shikimate3-phosphate (EPSP) synthase inhibitors, transport inhibitor response (TIR) 1 auxin receptors (synthetic auxins), auxin transport inhibitors, glutamine synthetase inhibitors, phytoene desaturase inhibitors, bleaching 4-Hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors, carotenoid biosynthesis inhibitors (unknown target), microtubule inhibitors, long-chain fatty acid inhibitors (cell division inhibitors), cell wall synthesis inhibitors, mitosis microtubule organization inhibitors, and combinations therefore.

In embodiment 56, the invention provides a process according to any one of embodiments 53 to 55, wherein the herbicide is selected from amidosulfuron, azimsulfuron, bensulfuron-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethametsulfuron-methyl,

5

10

15

20

ethoxysulfuron, flazasulfuron, flupyrsulfuron-methyl-sodium, foramsulfuron, halosulfuron-methyl, imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfuron-methyl, prosulfuron, pyrazosulfuron-ethyl, rimsulfuron, sulfometuron-methyl,

PCT/GB2018/053278

sulfosulfuron, thifensulfuron-methyl, triasulfuron, tribenuron-methyl, trifloxysulfuron,

triflusulfuron-methyl, tritosulfuron, imazapic, imazamethabenz-methyl, imazamox, imazapyr, imazaquin, imazethapyr, cloransulam-methyl, diclosulam, florasulam, flumetsulam, metosulam, penoxsulam, bispyribac-sodium, pyribenzoxim, pyriftalid, pyrithiobac-sodium, pyriminobac-methyl, flucarbazone-sodium, propoxycarbazone-sodium, glyphosate, sulfosate, clomeprop, 2,4-D, 2,4-DB, dichlorprop (2,4-DP), MCPA, MCPB, mecoprop (MCPP or CMPP), chloramben,

dicamba, TBA, clopyralid, fluroxypyr, picloram, triclopyr, quinclorac, Quinmerac, benazolinethyl, naptalam, diflufenzopyr-sodium, glufosinate-ammonium, bialaphos (bilanaphos),
Norflurazon, diflufenican, picolinafen, beflubutamid, fluridone, flurochloridone, flurtamone,
mesotrione, sulcotrione, isoxachlortole, isoxaflutole, benzofenap, pyrazolynate, pyrazoxyfen,
Benzobicyclon, bromobutide, (chloro)-flurenol, Cinmethylin, Cumyluron, Dazomet, dymron

daimuron), methyl-dymron (methyl-dimuron), etobenzanid, fosamine, indanofan, metam, oxaziclomefone, oleic acid, pelargonic acid, pyributicarb, amitrole, benefin (benfluralin), butralin, dinitramine, ethalfluralin, oryzalin, pendimethalin, trifluralin, amiprophos-methyl, butamiphos, dithiopyr, thiazopyr, propyzamide (pronamide), tebutam, propyzamide (pronamide), tebutam, chlorthal-dimethyl (DCPA), acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, metazachlor, metolachlor, pethoxamid, pretilachlor, propachlor, propisochlor, thenylchlor,

diphenamid, napropamide, naproanilide, flufenacet, mefenacet, fentrazamide, anilofos, cafenstrole, piperophos, dichlobenil, chlorthiamide, chlorpropham, propham, carbetamide, and combinations thereof.

25 In embodiment 57, the invention provides a process according to any one of embodiments 53 to 56, wherein the herbicide is selected from amidosulfuron, azimsulfuron, bensulfuron-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethametsulfuron-methyl, ethoxysulfuron, flazasulfuron, flupyrsulfuron-methyl-sodium, foramsulfuron, halosulfuron-methyl, imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, 30 primisulfuron-methyl, prosulfuron, pyrazosulfuron-ethyl, rimsulfuron, sulfometuron-methyl, sulfosulfuron, thifensulfuron-methyl, triasulfuron, tribenuron-methyl, trifloxysulfuron, triflusulfuron-methyl, tritosulfuron, imazapic, imazamethabenz-methyl, imazamox, imazapyr, imazaquin, imazethapyr, cloransulam-methyl, diclosulam, florasulam, flumetsulam, metosulam, penoxsulam, bispyribac-sodium, pyribenzoxim, pyriftalid, pyrithiobac-sodium, pyriminobac-35 methyl, flucarbazone-sodium, propoxycarbazone-sodium, glyphosate, sulfosate, benazolin-ethyl, glufosinate-ammonium, bialaphos (bilanaphos), norflurazon, diflufenican, picolinafen, beflubutamid, fluridone, flurochloridone, flurtamone, mesotrione, sulcotrione, isoxachlortole,

isoxaflutole, benzofenap, pyrazolynate, pyrazoxyfen, Benzobicyclon, bromobutide, (chloro)-flurenol, Cinmethylin, Cumyluron, Dazomet, dymron (daimuron), methyl-dymron (methyl-dimuron), etobenzanid, fosamine, indanofan, metam, oxaziclomefone, oleic acid, pelargonic acid, pyributicarb, benefin (benfluralin), butralin, dinitramine, ethalfluralin, oryzalin, pendimethalin, trifluralin, amiprophos-methyl, butamiphos, dithiopyr, thiazopyr, propyzamide (pronamide), tebutam, propyzamide (pronamide), tebutam, chlorthal-dimethyl (DCPA), chlorpropham, propham, carbetamide, and combinations thereof.

In embodiment 58, the invention provides a process according to any one of embodiments 53 to 57, wherein the herbicide is selected from norflurazon, diflufenican, picolinafen, beflubutamid, fluridone, flurochloridone, flurtamone, chlorpropham, propham, carbetamide, and combinations thereof; most preferably chlorpropham.

In embodiment 59, the invention provides a process for the preparation of a *Dunaliella* alga, comprising treating the *Dunaliella* alga by applying a herbicide selected from the group consisting of amino acid synthesis inhibitors, growth regulators, nitrogen metabolism inhibitor, pigment inhibitors (excluding phytoene desaturase inhibitors), seedling root growth inhibitors, seedling shoot growth inhibitors, cell wall synthesis inhibitors, mitosis microtubule organisation inhibitors, and combinations thereof.

20

25

5

10

15

In embodiment 60, the invention provides a process according to embodiment 59, wherein the herbicide is selected from acetolactate synthase (ALS) inhibitors, 5-enolpyruvyl-shikimate3-phosphate (EPSP) synthase inhibitors, transport inhibitor response (TIR) 1 auxin receptors (synthetic auxins), auxin transport inhibitors, glutamine synthetase inhibitors, bleaching 4-Hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors, carotenoid biosynthesis inhibitors (unknown target), microtubule inhibitors, long-chain fatty acid inhibitors (cell division inhibitors), cell wall synthesis inhibitors, mitosis microtubule organization inhibitors, and combinations therefore.

In embodiment 61, the invention provides a process according to embodiment 59 or 60, wherein the herbicide is selected from amidosulfuron, azimsulfuron, bensulfuron-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethametsulfuron-methyl, ethoxysulfuron, flazasulfuron, flupyrsulfuron-methyl-sodium, foramsulfuron, halosulfuron-methyl, imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfuron-methyl, prosulfuron, pyrazosulfuron-ethyl, rimsulfuron, sulfometuron-methyl, sulfosulfuron, thifensulfuron-methyl, triasulfuron, tribenuron-methyl, trifloxysulfuron, triflusulfuron-methyl, tritosulfuron, imazapic, imazamethabenz-methyl, imazamox, imazapyr, imazaquin, imazethapyr,

5

10

15

20

25

30

35

cloransulam-methyl, diclosulam, florasulam, flumetsulam, metosulam, penoxsulam, bispyribacsodium, pyribenzoxim, pyriftalid, pyrithiobac-sodium, pyriminobac-methyl, flucarbazone-sodium, propoxycarbazone-sodium, glyphosate, sulfosate, clomeprop, 2,4-D, 2,4-DB, dichlorprop (2,4-DP), MCPA, MCPB, mecoprop (MCPP or CMPP), chloramben, dicamba, TBA, clopyralid, fluroxypyr, picloram, triclopyr, quinclorac, Quinmerac, benazolin-ethyl, naptalam, diflufenzopyr-sodium, glufosinate-ammonium, bialaphos (bilanaphos), mesotrione, sulcotrione, isoxachlortole, isoxaflutole, benzofenap, pyrazolynate, pyrazoxyfen, Benzobicyclon, bromobutide, (chloro)flurenol, Cinmethylin, Cumyluron, Dazomet, dymron (daimuron), methyl-dymron (methyldimuron), etobenzanid, fosamine, indanofan, metam, oxaziclomefone, oleic acid, pelargonic acid, pyributicarb, amitrole, benefin (benfluralin), butralin, dinitramine, ethalfluralin, oryzalin, pendimethalin, trifluralin, amiprophos-methyl, butamiphos, dithiopyr, thiazopyr, propyzamide (pronamide), tebutam, propyzamide (pronamide), tebutam, chlorthal-dimethyl (DCPA), acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, metazachlor, metolachlor, pethoxamid, pretilachlor, propachlor, propisochlor, thenylchlor, diphenamid, napropamide, naproanilide, flufenacet, mefenacet, fentrazamide, anilofos, cafenstrole, piperophos, dichlobenil, chlorthiamide, chlorpropham, propham, carbetamide, and combinations thereof.

In embodiment 62, the invention provides a process according to any one of embodiments 59 to 61, wherein the herbicide is selected from amidosulfuron, azimsulfuron, bensulfuron-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethametsulfuron-methyl, ethoxysulfuron, flazasulfuron, flupyrsulfuron-methyl-sodium, foramsulfuron, halosulfuron-methyl, imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfuron-methyl, prosulfuron, pyrazosulfuron-ethyl, rimsulfuron, sulfometuron-methyl, sulfosulfuron, thifensulfuron-methyl, triasulfuron, tribenuron-methyl, trifloxysulfuron, triflusulfuron-methyl, tritosulfuron, imazapic, imazamethabenz-methyl, imazamox, imazapyr, imazaquin, imazethapyr, cloransulam-methyl, diclosulam, florasulam, flumetsulam, metosulam, penoxsulam, bispyribac-sodium, pyribenzoxim, pyriftalid, pyrithiobac-sodium, pyriminobacmethyl, flucarbazone-sodium, propoxycarbazone-sodium, glyphosate, sulfosate, benazolin-ethyl, glufosinate-ammonium, bialaphos (bilanaphos), mesotrione, sulcotrione, isoxachlortole, isoxaflutole, benzofenap, pyrazolynate, pyrazoxyfen, Benzobicyclon, bromobutide, (chloro)flurenol, Cinmethylin, Cumyluron, Dazomet, dymron (daimuron), methyl-dymron (methyldimuron), etobenzanid, fosamine, indanofan, metam, oxaziclomefone, oleic acid, pelargonic acid, pyributicarb, benefin (benfluralin), butralin, dinitramine, ethalfluralin, oryzalin, pendimethalin, trifluralin, amiprophos-methyl, butamiphos, dithiopyr, thiazopyr, propyzamide (pronamide), tebutam, propyzamide (pronamide), tebutam, chlorthal-dimethyl (DCPA), chlorpropham, propham, carbetamide, and combinations thereof.

PCT/GB2018/053278

In embodiment 63, the invention provides a process according to any one of embodiments 59 to 62, wherein the herbicide is selected from chlorpropham, propham, carbetamide, and combinations thereof; most preferably chlorpropham.

5 In embodiment 64, the invention provides a process for preparing a Dunaliella alga, or extract thereof; or a powdered Dunaliella alga, or extract thereof; according to any one of embodiments 24 to 30, wherein the process is as defined in any one of embodiments 53 to 63.

In embodiment 65, the invention provides the use of a *Dunaliella* alga, or extract thereof, or a powdered Dunaliella alga, or extract thereof; as defined in any one of embodiments 1 to 30; as a food colourant or food ingredient; or as a health supplement.

In embodiment 66, the invention provides the use of a *Dunaliella* alga, or extract thereof, or a powdered Dunaliella alga, or extract thereof; as defined in any one of embodiments 1 to 30; in a cosmetic composition.

In embodiment 67, the invention provides a *Dunaliella* alga, or extract thereof, or a powdered Dunaliella alga, or extract thereof, as defined in any one of embodiments 1 to 30; or a composition as defined in embodiment 31, for use in therapy.

20

25

30

35

10

15

## **DEFINITIONS**

The term 'Dunaliella alga' as used herein refers to the multiple strains of Dunaliella that produce carotenoids. Nomenclature of these strains has not historically been consistent. For example, Dunaliella barawil is considered by some references to be a strain of Dunaliella salina, but is considered by others to be a different strain. Figure 11 shows the grouping of *Dunaliella* strains by the Marine Biological Association (MBA), together with the nomenclature used herein. Preferably, the term 'Dunaliella algae, as used herein refers to any strain of Dunaliella salina salina, Dunaliella salina rubeus, Dunaliella salina bardawil and Dunaliella tertiolecta, as classified in Figure 11. Particularly preferred strains are PLY DF15 (CCAP 19/41), PLY DF17, PLY DF40 (CCAP 19/40), and UTEX2538.

The term 'grown or cultivated under natural light or white light conditions' as used herein, refers to Dunaliella algae growing, or specifically cultivated, in ponds, lakes, lagoons, raceways or closed vessels under natural light or under artificial white light.

The term 'raceway' as used herein, refers to a shallow pond that uses sunlight as the light source and paddlewheels to provide the flow to circulate algae, water and nutrients keeping the algae suspended in the water, and circulating them back to the surface on a regular frequency. The ponds are operated continuously with carbon dioxide or flue gas containing CO2 and nutrients are fed constantly or by batch to the ponds.

The term 'cascade raceway' as used herein, refers to a raceway which uses gravity instead of a paddlewheel to promote the mixing of the culture as it flows on the surface of inclined surfaces. After each cycle it is necessary to reposition the culture on the top part of the cascade through a pump or another device thus ensuring the flow cycle is closed.

5

10

15

20

25

30

35

The term 'photobioreactor' (PBR) as used herein, refers to a closed vessel or bioreactor, which incorporates some type of light source for photo- or mixo-trophic cultivation of algae. The light source is usually sunlight, but can also include artificial lighting. All essential nutrients must be introduced into the system to allow algae to grow and be cultivated. A photobioreactor can be operated in "batch mode" but it is also possible to introduce one or multiple continuous streams of process water containing nutrients, air and carbon dioxide. Temperature control (heating and cooling) are easily achievable. Many photobioreactor designs have been created and include vertical Green-wall flat panels (Green-walls, GW) comprising a thin layer of liquid (5-10 cm) contained in an aerated transparent plastic bag supported by a metal framework, and tubular photobioreactors, which consist of vertical or horizontally displayed transparent tubes, which can be stacked in groups to yield parallel fence-like vertical sets, and connected through piping accessories to a tank/degassing column, where most of the automation equipment is located, as well as the inlets and outlets for all the utilities. Culture mixing is ensured by pumping (in some cases also compressed air).

The term 'increased content of' as used herein, refers to an increase in the content of the carotenoid relative to the content found in *Dunaliella* algae which is grown or cultivated under natural conditions, i.e. under natural light or white light conditions and without herbicide treatment.

The term 'early orange phase' as used herein, refers to the growth phase that typifies the start of carotenogenesis, and is usually associated with the onset of stress related to deficiency in nitrate, sulfate, and phosphate in the culture media as well as high light intensity and high sodium chloride concentration. The carotenoid: chlorophyll ratio in cells is typically 3 or more.

The term 'log growth phase' as used herein refers to the period of algal growth characterized by cell doubling (also known as the logarithmic phase or exponential phase). The carotenoid: chlorophyll ratio in cells is typically around 1.

5 The term 'powdered *Dunaliella* alga' as used herein refers to a powdered product of *Dunaliella* alga which may be obtained by spray-drying or freeze-drying or any other method of dehydration.

The term 'light of wavelength' or 'wavelength in the range of' as used herein, refers to light having a wavelength of light emittance in the specified range by the source. For the avoidance of doubt the wavelength of light range includes either a single wavelength of light emittance within the specified range or any number of single wavelengths of light emittance within the specified range.

The term 'herbicide' as used herein refers to a composition which controls, suppresses or destroys plant growth. The herbicide may be defined by the mechanism of action, including phytoene desaturase inhibitors, phytochrome inhibitors, auxin-type (synthetic auxin) herbicides), cell division inhibitors, enolpyruvylshikimate 3-phosphate synthase enzyme (EPSPS) inhibitors, acetyl coenzyme A carboxylase (ACCase) inhibitors, acetolactate synthase (ALS) inhibitors, photostem II inhibitors, photostem I inhibitors, and 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors.

The invention is illustrated by the following examples.

#### Example 1

10

15

35

strains:

Dunaliella algae were cultured in the laboratory in an ALGEM Environmental Modeling Labscale Photobioreactor (Algenuity, UK), at 25 °C. Approximately 5 x 10<sup>7</sup> cells were inoculated in 500 ml Modified Johnsons Medium (Borowitzka, Algal growth media and sources of cultures, in
 Microalgal Biotecnology. Borowitzka, L.J. (Eds.), 1988, pp. 456–465) containing 1.5 M NaCl and placed under a cycle of 12h/12h Light/Dark conditions. Cells were grown under 200 μmol photons · m<sup>-2</sup> · s<sup>-1</sup> of white LED light. In one set of experiments cells were cultivated to a cell density of ~0.5 x 10<sup>6</sup> cells mL<sup>-1</sup> and then the cultures were diluted with fresh medium to a cell density of ~0.2 x 10<sup>6</sup> cells mL<sup>-1</sup>. Under these conditions cells were in the early orange phase of
 growth but not placed under nutrient stress. The cultures were then exposed to either white LED light, red LED light, or blue LED light at the same light intensity of 1000 μmol m<sup>-2</sup> s<sup>-1</sup>, or white LED light of 1000 μmol m<sup>-2</sup> s<sup>-1</sup> covered with one of three different red filters (filter 26 Bright red, 27 Medium Red and 787 Marius Red supplied by LEE Filters) for 48 hours. Each light condition was set up in at least triplicate. *Dunaliella* algae used in these experiments were the following

PLY DF15, classified as *D salina rubeus* (and held by the Marine Biological Association Culture Collection, origin Israel) and also classified as CCAP 19/41 and held by the Culture Collection of Algae and Protozoa (CCAP).

PLY DF17, classified as *D. salina salina* (held by the Marine Biological Association Culture Collection, origin Israel)

PLY DF40, classified as *D. salina bardawil* (held by the Marine Biological Association Culture Collection, origin Spain) and also classified as *D. salina* CCAP 19/40 and held by the Culture Collection of Algae and Protozoa (CCAP).

UTEX 2538, classified as D. salina bardawil (Culture Collection of Algae and Protozoa (CCAP))

# 10

15

20

25

30

## Example 2

In a second set of experiments cells were cultivated to the log phase of growth and then kept in the dark for 36 hours for dark adaption. After dark adaption, the cultures were exposed to continuous blue or red LED light at different light intensities of 200, 500, and 1000  $\mu$ mol photons · m<sup>-2</sup> · s<sup>-1</sup> for 48 hours. Each growth condition was set up in at least triplicate.

## Example 3

In a third set of experiments, *Dunaliella* algae were cultivated at 25 °C under 200  $\mu$ mol photons · m<sup>-2</sup> · s<sup>-1</sup> of white LED light to log phase and then kept in the dark for 36 hours for dark adaption. Then the cultures were exposed to continuous blue or red LED light at the light intensity of 1000  $\mu$ mol photons · m<sup>-2</sup> · s<sup>-1</sup> at 15 °C compared to 25 °C for 48 hours.

Cell concentration: Cell concentration was determined by counting the number of cells in culture broth using a haemocytometer, after fixing with 2 % formalin. Samples were taken at 0, 24 and 48 hours to determine the cellular contents of carotenoids and chlorophyll and the composition of the carotenoids.

**Pigment analysis:** 1 ml culture broth was centrifuged at 3,000 g in a bench-top centrifuge for 5 min. to harvest the algal biomass and pigments were extracted from the biomass using 1ml of 80 % (v/v) acetone. After clarification at the centrifuge, the absorbance of the acetone extract was measured at 480 nm in a spectrophotometer. The content of total carotenoids was calculated according to Strickland & Parsons ( Strickland, J. & Parsons, T.R., 1972. *A practical handbook of seawater analysis* 2nd ed., Fish Res Board Can Bull.):

Total Carotenoids ( $\mu g \cdot ml^{-1}$ ) = 4.0 \* Abs<sub>480nm</sub>, where Abs<sub>480nm</sub> is the absorbance of 80 % acetone extract measured at 480 nm.

Chlorophyll a, b and total Chlorophyll were evaluated by measuring the absorbance of the acetone extract at 664 nm and 647nm and calculated according to Porra, R.J., Thompson, W.A. & Kriedemann, P.E., 1989. Determination of accurate extinction coefficients and simultaneous

equations for assaying chlorophylls a and b extracted with four different solvents: verification of the concentration of chlorophyll standards by atomic absorption spectroscopy. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 975(3), pp.384–394.:

Chl a 
$$(\mu g \cdot ml^{-1}) = (12.25 * Abs_{64nm}) - (2.55 * Abs_{64nm});$$

5 Chl b (
$$\mu$$
g · ml<sup>-1</sup>) = (20.31 \* Abs<sub>647nm</sub>) – (4.91 \* Abs<sub>664nm</sub>),

Total Chl (
$$\mu$$
g · ml<sup>-1</sup>) = Chl a ( $\mu$ g · ml<sup>-1</sup>) + Chl b ( $\mu$ g · ml<sup>-1</sup>),

where  $Abs_{647nm}$  and  $Abs_{664nm}$  refer to the absorbance of the 80 % acetone extract measured at 664 nm and 647 nm respectively.

The compositions of pigments were analysed using an HPLC with fitted with diode-array detection (DAD). 15 ml culture broth was centrifuged at 3,000 g in a bench-top centrifuge for 5 min. to harvest the algal biomass as before. Algal biomass was extracted with 10 ml MTBE-MeOH (20:80), after sonication for 20 s. Each sample was clarified by centrifugation at 3,000 g for 10 min then filtered through a 0.45 μm filter into amber HPLC vials. The samples were analysed using a YMC30 250 X 4.9 mm I.D S- 5μ HPLC column with DAD at 25 °C, and isocratic elution with 80 % methanol: 20 % MTBE, flow rate of 1 mL min<sup>-1</sup>, pressure of 90 bar. The quantities of β-carotene in the biomass were estimated using a β-carotene standard curve prepared with synthetic *all-trans* β-carotene from Sigma, and the quantities of phytoene and α-carotene, with reference to standards of each from Sigma. Each experiment was carried out in at least triplicate.

# 20 Example 4

10

15

25

30

35

Treatment of D. salina cultures with red light included in the cultivation cycle was observed to increase both the ratio of 9-cis to all-trans  $\beta$ -carotene and the amount of carotenoid compared to cultivation under a white:dark light cycle, with the greatest increases occurring with continuous red light, whether applied with red LED or with red filters. Compensation for the intensity of light emitted by LED lights may be required when red filters are applied as covers to LED lights. The results are presented in Figure 12. All treatments with red light included in the cycle increased both the ratio of 9-cis to all-trans  $\beta$ -carotene compared to the natural condition and the amount of carotenoid, with the greatest increases occurring with continuous red light, whether applied with red LED or with red filters, but red filters applied to LED lights reduces the light intensity emitted and consequently the cellular productivity.

# Example 5

Treatment of *D. salina* cultures with far-red light of 730 nm was found to be as effective in increasing  $\beta$ -carotene production and the *9-cis/all-trans* ratio as red light transmitted by Lee Filter 027 (600-700nm). The carotenoids, *9-cis/all-trans* ratio and chlorophyll content of cultures under far red and red light were identical. Both far red light and red light increased the *9-cis/all-trans* ratio from ~1.5 to ~2.0 compared to white light alone. By contrast with LED light of wavelength

PCT/GB2018/053278

830 nm applied for 3 days, the cells did not divide, as was also found for cells placed in the dark for 3 days. The 9-cis/all-trans β-carotene ratio decreased for cells placed in the dark or treated with 830 nm light compared to untreated cells and the yield of carotenoids and β-carotene also slightly decreased. The results are presented in Figure 13.

5

10

# Example 6

Treatment of D. salina cultures with red light-dark cycles of increasing red light cycle duration was found to increase cell density, total carotenoids and 9-cis: all-trans ratio, with the greatest effect being meted with continuous red light. 9-cis-β-Carotene content was found to continuously increase with continuous red light for 140 h, whereas total carotenoid content showed no further increase after 72 h, which may reflect decreasing cellular synthetic capacity, since total chlorophyll content declines continuously in continuous red light for 140 h. Results are presented in Figure 14.

## Example 7

Treatment of D. salina cultures cultivated under red light with phytoene desaturase inhibitor 15 herbicides was found to result in a significantly higher amount of phytoene when compared to cultivation under white light. Results are presented in Figure 15.

# Example 8

D. salina cultures were treated with herbicides which inhibit cell division, such as chlorpropham 20 (CIPC), aminopyralid, carbetamide and chlorsulfuron, or with phytochrome inhibitors such as glyphosate. The content of both phytoene and phytofluene as well as the content of coloured carotenoids were found to have increased when D. salina is cultured in the presence of the herbicides, and cultivation under red light was found to magnify the effects. Results are presented 25 in Table 4 and Figure 16.

# Example 9

30

35

D. salina cultures were treated with chlorpropham. The cellular content of colorless carotenoids was found to increase by more than 30-fold and the yield of the colorless carotenoids was found to increase more than 10-fold compared to untreated cultures. The optimal concentration range of chlorpropham added to the cultures was determined to be 10-50 μM. Cell density stopped increasing once chlorpropham was added, and carotenoids in particular phytoene and phytofluene started to accumulate. Chlorpropham is preferably added to the cultures when a high cell density is achieved.

Figure 1. HPLC profiles of carotenoid extracts from *Dunaliella salina* exposed to continuous white light (A), red light (B) and blue light (C) at 1000  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup> for 48 hours after initial growth to early orange phase of the growth cycle in white light. Peak 1: *all-trans*  $\beta$ -carotene; peak 2: 9-*cis*- $\beta$ -carotene. The Figure shows absorbance profile at 450nm.

5

10

15

20

25

30

35

Figure 2. Effect of different light treatments on the ratio of 9-cis and all-trans  $\beta$ -carotene (A); the cellular content of all-trans  $\beta$ -carotene and of 9-cis  $\beta$ -carotene (B); and the amount of 9-cis  $\beta$ -carotene as a % of the total amount of carotenoids (C) in Dunaliella salina when cultivated to early orange phase until light treatment (T0) and then subjected to different light treatments for 48 hours.

Cells were cultured in light:dark 12h:12h in incubators with white light to early orange phase (cell density of  $\sim$ 0.5 x 10<sup>6</sup> cells mL<sup>-1</sup>; carotenoid: chlorophyll ratio  $\sim$  3) and then cultures were diluted with fresh medium to a cell density of  $\sim$ 0.2 x 10<sup>6</sup> cells mL<sup>-1</sup> (No nutrient stress). The cultures were then exposed to either white LED light, red LED light, or blue LED light at the same light intensity of 1000 µmol m<sup>-2</sup> s<sup>-1</sup>, or white LED light of 1000 µmol m<sup>-2</sup> s<sup>-1</sup> covered with one of three different red filters (Lee filter 26 Bright red, 27 Medium Red and 787 Marius Red, see Figure 9) for 48 hours. Each light condition was set up in at least triplicate. The data show clearly the increase in 9-cis: all-trans  $\beta$ -carotene ratio and increase in 9-cis  $\beta$ -carotene as a % of total carotenoids after exposure to red light. Red light applied using filters may vary in total light intensity delivered to cells (see Figure 9 for examples of transmission % using the filters illustrated). This effect is most notable with use of the 787 Marius Red filter, which cut out approximately 98% of the light intensity applied such that cells received only approximately 10-17 µmol m<sup>-2</sup> s<sup>-1</sup> light intensity of the red light. The effect of red light delivered with the 787 Marius Red filter still prevailed to increase the ratio of 9-cis-: all-trans  $\beta$ -carotene and the amount of 9-cis  $\beta$ -carotene as a % of the total amount of carotenoids.

Figure 3. Effect of different light treatments on the cellular content of total carotenoids and chlorophyll (A), and of phytoene and of  $\alpha$ -carotene (B) in *Dunaliella salina* when cultivated to early orange phase until light treatment (T0) and then subjected to different light treatments for 48 hours.

Cells were cultured in light:dark 12h:12h in incubators with white light to early orange phase (cell density of  $\sim 0.5 \times 10^6$  cells mL<sup>-1</sup>; carotenoid: chlorophyll ratio  $\sim 3$ ) and then cultures were diluted with fresh medium to a cell density of  $\sim 0.2 \times 10^6$  cells mL<sup>-1</sup> (no nutrient stress). The cultures were then exposed to either white LED light, red LED light, or blue LED light at the same light intensity of 1000  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup>, or white LED light of 1000  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup> covered with one of three different

10

15

20

25

30

35

red filters (Lee filter 26 Bright red, 27 Medium Red and 787 Marius Red, see Figure 9) for 48 hours. Each light condition was set up in at least triplicate.

PCT/GB2018/053278

These data show that the cellular content of chlorophyll and in turn phytoene and  $\alpha$ -carotene may vary to compensate for reduced light availability using filters (see Figure 9 for examples of transmission % using the filters illustrated). This effect is most notable with use of the 787 Marius Red filter, which cut out approximately 98% of the light intensity applied such that cells received only approximately 10-17  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup> light intensity of the red light.

Figure 4. Effect of different light treatments on the cellular content of 9-cis β-carotene and all-trans β-carotene (A) and the ratio of 9-cis and all-trans β-carotene (B) in Dunaliella salina when cultivated to mid-log phase of growth until light treatment (T0) and then subjected to different light treatments. Cells were cultured in light:dark 12h:12h white light growth regime to mid-log phase of the growth cycle  $(0.1-0.2 \times 10^6 \text{ cells mL}^{-1}; \text{ carotenoid: chlorophyll ratio } \sim 1)$  then transferred to a further 24h dark (Dark T0) before being exposed to continuous red LED light at 1000 µmol m<sup>-2</sup> s<sup>-1</sup> for 24 hours (Red 24h). Cells were then treated for 24 hours under either red light (Red 48), a mix of 1:1 red and blue light (Red 24h + mix 24h), blue light (Red 24h + blue 24h) at the same light intensity of 1000 μmol m<sup>-2</sup> s<sup>-1</sup> or dark (Red 24h + dark 24h). Each light condition was set up at least in triplicate. These data show clearly a 4-fold increase in 9-cis-βcarotene content after exposure to 48h red light (9.75±1.09 pg cell<sup>-1</sup>) compared to dark-adapted cells (2.39±0.22 pg cell<sup>-1</sup>). The ratio of 9-cis- $\beta$ -carotene: all-trans  $\beta$ -carotene after 48h red LED light was 1.58 whereas that for dark-adapted cells was 0.59 (see Table 2). In the cycle of red light 24h followed by dark 24h, the amount of 9-cis- $\beta$ -carotene was maintained constant, but in the cycle of red light 24h followed by blue light 24h, approximately 35% of 9-cis- $\beta$ -carotene was lost. This effect was negated by using the 1:1 red/blue light mix instead of blue light alone. The total carotenoid content increased from 8.58±1.09 pg cell<sup>-1</sup> (dark-adapted cells) to 22.47±2.34

Figure 5. Effect of different light treatments on the cellular content of chlorophyll and total carotenoids (A) and the ratio of total carotenoids to total chlorophyll (B) and on the cellular content of phytoene and *all-trans-\alpha*-carotene in *Dunaliella salina*. Cells were cultured in light:dark 12h:12h white light growth regime to mid-log phase of the growth cycle (0.1-0.2 x  $10^6$  cells mL<sup>-1</sup>; carotenoid: chlorophyll ratio  $\sim 1$ ) then transferred to a further 24h dark (Dark T0) before being exposed to continuous red LED light at 1000 µmol m<sup>-2</sup> s<sup>-1</sup> for 24 hours (Red 24h). Cells were then treated for 24 hours under either red light (Red 48), a mix of 1:1 red and blue light (Red 24h + mix 24h), blue light (Red 24h + blue 24h) at the same light intensity of 1000 µmol m<sup>-2</sup> s<sup>-1</sup> or dark (Red 24h + dark 24h). Each light condition was set up at least in triplicate.

pg cell<sup>-1</sup> after treatment with red light for 48h (2.6-fold increase) (see Figure 5).

The total carotenoid content increased from  $8.58\pm1.09$  pg cell<sup>-1</sup> (dark-adapted cells) to  $22.47\pm2.34$  pg cell<sup>-1</sup> after treatment with red light for 48h (2.6-fold increase). The chlorophyll content decreased under these conditions such that the ratio of carotenoids:chlorophyll increased from 2 in white light on exposure to red light for 24h, to 5.5.

5

10

15

20

Figure 6. Cellular content of 9-cis  $\beta$ -carotene (A), all-trans  $\beta$ -carotene (B), the ratio of 9-cis and all-trans  $\beta$ -carotene (C), the content of phytoene (D) and the content of all-trans- $\alpha$ -carotene in Dunaliella salina cells treated with either continuous blue or red LED light at three different light intensities of 200, 500 and 1000  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup> for 48 hours. Cells were cultured in light:dark 12h:12h white light growth regime to mid-log phase of the growth cycle  $(0.1-0.2 \times 10^6 \text{ cells mL}^{-1}$ ; carotenoid: chlorophyll ratio  $\sim$  1) then transferred to a further 24h dark (Dark T0) before exposure. Each light condition was set up at least in triplicate. (See also Table 5). These data show that red LED light specifically enhances production of 9-cis- $\beta$ -carotene relative to all-trans- $\beta$ -carotene. Furthermore, the effect on 9-cis- $\beta$ -carotene and on all-trans- $\beta$ -carotene is independent of light intensity.

- Figure 7. Cellular content of total carotenoids (A), total chlorophyll (B) and the ratio of total carotenoids to total chlorophyll (C) in *Dunaliella salina* cells treated with either continuous blue or red LED light at three different light intensities of 200, 500 and 1000  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup> for 48 hours. Cells were cultured in light:dark 12h:12h white light growth regime to mid-log phase of the growth cycle (0.1-0.2 x 10<sup>6</sup> cells mL<sup>-1</sup>; carotenoid: chlorophyll ratio ~ 1) then transferred to a further 24h dark (Dark T0) before exposure. Each light condition was set up at least in triplicate. These data show that red LED light specifically enhances production of total carotenoids.
- Figure 8. Effect of temperature on cellular content of 9-cis β-carotene and all-trans β-carotene (A) and the ratios of 9-cis and all-trans β-carotene (B) in Dunaliella salina cells exposed to red or blue LED light. Cells were cultured in light:dark 12h:12h white light growth regime to mid-log phase of the growth cycle (0.1-0.2 x 10<sup>6</sup> cells mL<sup>-1</sup>) then transferred to a further 24h dark (Dark T0) before exposure to either continuous blue or red LED light at 1000 μmol m<sup>-2</sup> s<sup>-1</sup> for 48 hours at 15 °C or 25 °C for 48 hours. Each light condition was set up at least in triplicate. Reduction by 10°C reduced the cellular content of all-trans-β-carotene but the cellular content of 9-cis-β-carotene was maintained and consequently the ratio of 9-cis: all-trans β-carotene increased to 2.2. (Compare Figure 4).
- Figure 9: The light transmission (Y%) for each wavelength (nm) of typical filters that may be used to transmit red light, such as: (from Lee Filters) 26 Bright red (Transmission 8.6%), 27 Medium

Red (Transmission 3.6%),787 Marius Red (Transmission 1.0%). Filters that eliminate blue light will also be effective, such as: (from Lee Filters), 105 Orange (Transmission 41.3%), and 010 Medium Yellow (Transmission 86.5%). Figure 9 (F) shows the typical relative spectral power distribution of white, blue and red LED lights.

5

10

Figure 10: Effect of red and blue LED light on *all-trans*  $\beta$ -carotene. (A) Red light under nitrogen; (B) Red light in air; (C) Blue light in air. *All-trans-β*-carotene (Sigma) was dissolved in chloroform to a final concentration of 2.4 μM and vials were thoroughly flushed with either nitrogen or air, sealed and incubated for 24h at 25 °C under LED lights. (A) red, nitrogen; (B), red, air; (C) blue, nitrogen or air. The same results as (A) were obtained for dark under nitrogen or air. In (B) 40% destruction of *all-trans* β-carotene was recorded in red light under air, whereas in (C) in blue light, *all-trans* β-carotene was fully destroyed within the same time frame. In (A) (red light under nitrogen) no reaction of β-carotene was detected. These data show that blue light is more damaging to *all-trans* β-carotene than is red light.

15

20

25

30

**Figure 11: Classification of** *Dunaliella* **strains** (unpublished) as provided by the Director of The Marine Biological Association Culture Collection, Citadel Hill Plymouth PL1 2PB.

Figure 12: Cellular content of (A) 9-cis  $\beta$ -carotene and all-trans  $\beta$ -carotene, (B) 9-cis/all-trans ratio (C) yield of carotenoids ( $\mu$ g ml<sup>-1</sup>) and (D) cellular content of total carotenoids of D. salina cultures grown under different light cycles. T0, amounts at time 0.

Cultures of *D. salina* were grown to mid-log phase and then exposed to different 24h cycles of light treatment applied for 3 days. Biomass was harvested at mid-day on the 3<sup>rd</sup> day for analysis by HPLC. The cycles were as follows:

- (1) **8h white: 16h dark cycle,** 8h white light (500 μmol m<sup>-2</sup> s<sup>-1</sup>) followed by 16h dark to simulate a day-night cycle, for 72 h.
  - (2) **8h white: 16h red LED cycle,** 8h white light (500  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup>) followed by 16h red LED light (500  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup>), for 72 h.
  - (3) Continuous red LED, red LED light (500 μmol m<sup>-2</sup> s<sup>-1</sup>), for 72 h.
- (4) **8h LEE filter:16h dark,** LEE filter medium red 027 covered over white light (500 μmol m<sup>-2</sup> s<sup>-1</sup>) for 8h, followed by 16h dark, for 72 h.
- (5) **8h LEE filter + white LED: 16 h red LED cycle:** LEE filter medium red 027 covered over white LED light (500 μmol m<sup>-2</sup> s<sup>-1</sup>) for 8h, and red LED light (500 μmol m<sup>-2</sup> s<sup>-1</sup>) for 16 h, for 72 h.

- (6) 8h LEE filter + white LED + 24 h red LED cycle: LEE filter medium red 027 covered over white light (500  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup>) for 8h, together with red LED light (500  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup>) for 24 h, for 72 h.
- **Figure 13:** The effect of red light and far-red light of 730 nm applied to *D. salina* cultures for 48 h on the ratio of 9-cis: all-trans β-carotene (A), and of light of 830 nm on cell density (B), all-trans- and 9-cis β-carotene (C), on the ratio of 9-cis: all-trans β-carotene (D) and total carotenoids and β-carotene (E).

Cultures of D. salina were grown to a cell density of  $\sim 0.2$  million cells ml<sup>-1</sup> under white LED light and then transferred for either 48 h growth (A) or 60 h growth (B-D) under different lighting regimes which included

- (1) Continuous far-red light (730nm),
- (2) Continuous red light provided by covering white light with a red filter (LEE filter medium red 027), and
- (3) Continuous light at 830 nm supplied with a LED of wavelength 830 nm.
- 15 (4) Dark

10

20

25

30

The carotenoids, 9-cis/all-trans ratio and chlorophyll content of cultures under far red and red light were identical (A). Both far red light and red light increased the 9-cis/all-trans ratio from  $\sim 1.5$  to  $\sim 2.0$  compared to white light alone (A). Under LED light of wavelength 830 nm applied for 3 days, the cells did not divide, as was also found for cells placed in the dark for 3 days (B). The 9-cis/all-trans  $\beta$ -carotene ratio decreased for cells placed in either the dark or treated with 830 nm light compared to that recorded for the cells at the outset (T<sub>0</sub>) of the experiment (C), and the yield of carotenoids and  $\beta$ -carotene also slightly decreased, albeit not as much as cells placed in the dark (E). Figure 14: Effect of cultivating D. salina under different red/dark cycles. The data show the effect of reducing the duration of red light on (A) Cell density; (B) Cellular content of total carotenoids, (C) Carotenoids/Chlorophyll ratio, (D) cellular content of all-trans  $\beta$ -carotene, (E) cellular content of 9-cis  $\beta$ -carotene, (F) 9-cis/all-trans  $\beta$ -carotene ratio.

Cultures of D. salina were grown to a cell density of  $\sim 0.2$  million cells ml<sup>-1</sup> under white LED light and then transferred into red LED light growth cycles of different duration, which were maintained for 6 days. The light intensity of red LED light was set at 500  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup>. The cycles were as follows:

- (1) 10 min red LED on, 110 min off (8% cycle time with light)
- (2) 20 min red LED on 100 min off (17% cycle time with light)
- (3) 10 min red LED on, 50 min off (17% cycle time with light),
- (4) 20 min red LED on, 40 min off, (33% cycle time with light),
- 35 (5) 30 min red LED on 30 min off (50% cycle time with light),

10

(6) Continuous red LED light.

Figure 15 shows the cellular content of (A) phytoene, (B) 9-cis β-carotene, (C) all-trans β-carotene, (D) total β-carotene and (E) *9-cis/all-trans* β-carotene ratio in *D. salina* cultures treated at 25 °C for 48 h with different concentrations of the phytoene desaturase inhibitor herbicide norflurazon (5 and 50 μM) under white or red LED light at 200 μmol m<sup>-2</sup> s<sup>-1</sup>. Coloured carotenoids and phytoene contents were determined after separation using HPLC as before. When phytoene desaturase was inhibited, phytoene accumulated and a significantly higher amount of phytoene was produced under red light compared to white light (Figure 15 (A)). Furthermore, in red light *9-cis* β-carotene increased (Figure 15 B) at the expense of *all-trans* β-carotene (Figure 15 C) which was converted to *9-cis* β-carotene while no more *all-trans* β-carotene was synthesized (Figure 15 D), resulting in even higher *9-cis/all-trans* β-carotene ratio, more than double the ratio determined in white light (white light, 1.8; red light, 3.9) (Figure 15 E).

**Figure 16** shows the effect of cultivation of *D. salina* in the presence of chlorpropham.

- 15 (A): The effect of increasing concentrations of chlorpropham on (i) cellular content of phytoene; (ii) phytoene vield; (iii) cellular content of β-carotene; and (iv) total carotenoids.
  - (B): The effect of increasing white LED light intensity on phytoene production.
  - (C): The effect of red LED light (100-200 µmol m<sup>-2</sup> s<sup>-1</sup>) on phytoene production.
  - (D): The effect of red LED light of increasing light intensity on phytoene production.
- Chlorpropham stock solution of 1 M was added to cultures of *D. salina* to different final concentrations (0, 0.1, 1, 10, 20, 50 and 100 μM) and cultures were maintained in an incubator at 25 °C. Carotenoids profile was analysed for each culture by HPLC. For (A), cultures were maintained under continuously applied white LED light (~200 μmol m<sup>-2</sup> s<sup>-1</sup>) with different concentrations of chloropropham as shown. For (B) cultures were maintained in the presence of 20 μM chlorpropham, but under different intensities of continuously applied white LED light (50, 100, 200, 500, 1000 and 1500 μmol m<sup>-2</sup> s<sup>-1</sup>) as shown. For (C), cultures were maintained under continuously applied red LED light at 100-200 μmol m<sup>-2</sup> s<sup>-1</sup> in the presence of either 10 μM or 20 μM chlorpropham for 6 days. For (D) cultures were maintained under continuously applied red LED lights at different light intensities (200, 500, and 1000 μmol m<sup>-2</sup> s<sup>-1</sup>) for 48 hours in the presence of 20 μM chlorpropham.

The optimal concentration of chlorpropham for phytoene production was between 10-50  $\mu M$ .

10

20

25

30

After 6-days cultivation in white LED light in the presence of 20  $\mu$ M chlorpropham, the phytoene content in cells increased ca. 50-fold compared to that in untreated cells (untreated cells: 0.55  $\pm$  0.01 pg cell<sup>-1</sup>, treated cells 25.76  $\pm$  1.58 pg cell<sup>-1</sup>) whilst the final phytoene concentration in the cultures increased 10-fold (untreated cultures 0.35  $\pm$  0.01 mg L<sup>-1</sup>; treated 3.55  $\pm$  0.11 mg L<sup>-1</sup>). With increasing light intensity of applied white light, phytoene content per cell and yield increased: after just 4 days' cultivation, the phytoene content reached above 30 pg cell<sup>-1</sup> under 1500  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup>, giving a yield of 8.2 mg L<sup>-1</sup>. Under red light, cultures had higher phytoene contents than cultures maintained under white light with the same concentration of chlorpropham treatment.

**Figure 17** shows the effect of cultivation of *D. salina* in the presence of the herbicides aminopyralid, carbetamide, and chlorsulfuron (cell division inhibitors), and glyphosate (phytochrome inhibitor). All herbicides tested increased the content of phytoene per cell and the contents were further increased when cultures were maintained under red light.

- (A): Effect of increasing concentrations of herbicides on cellular content of (i) phytoene; (ii) phytoene yield, under continuous white light.
- 15 (B): Effect of red light applied to cultures of *D. salina* treated with either 50 μM aminopyralid or 50 μM glyphosate as representative cell division or phytochrome inhibitors respectively.

Cultures were maintained at 25 °C under continuous white or red LED light at  $\sim$ 200  $\mu$ mol m<sup>-2</sup> s<sup>-1</sup> and carotenoid contents determined daily by HPLC as before.

**Figure 18** provides data to substantiate the identity of phytoene and phytofluene in cultures of *D. salina*.

Samples were extracted using absolute ethanol and extracts were analysed using a YMC30 250 X 4.9 mm I.D S- 5μ HPLC column with DAD at 25 °C, and isocratic elution with 80 % methanol: 20 % MTBE, flow rate of 1 mL min<sup>-1</sup>, pressure of 90 bar. Alternatively they were analysed using a Waters Acquity UPCC (Waters, UK) instrument fitted with a Diode Array Detector and connected to a Synapt G2 HDMS (Waters, UK). The Synapt G2 was fitted with an electrospray source, and operated in positive ion mode over a mass range of 50-800 *m/z* units. Wavelength-dependent absorption was measured using the DAD, and operating in the wavelength range 200-700 nm. Phytoene was separated using an Acquity UPLC HSS C18 SB, 3.0 x 100 mm, 1.8 μm particle size, inlet conditions: scCO<sub>2</sub> (A); Methanol + 0.1% formic acid (v/v) (B); Make-up solvent: Methanol + 0.1% formic acid (v/v). Processing was carried out using MassLynx v4.1.

Time	Flow (ml/min)	%A	%B

Initial	1.5	95.0	5.0
5.00	1.5	75.0	25.0
5.10	1.5	50.0	50.0
6.00	1.5	50.0	50.0
8.00	1.5	95.0	5.0
10.00	1.5	95.0	5.0

10

15

- (A) UPC2 chromatogram (detection 285 nm) for (a) Norflurazon-treated cultures and (b) chlorpropham-treated cultures of *D. salina*.
- (B) Spectral properties of peaks RT of 2.57 min and 2.56 min in samples (a) and (b) respectively and overlay of the spectra. λmax at 282nm, 293nm and 271nm correspond to published λmax values for phytoene.
- (C) Elemental Composition Analysis of peak at RT = 2.57 min.
- (D) Extracted Ion Chromatogram for  $m/z = (545.5 \pm 0.5)$  Da for peak at RT = 2.57 min.
- (E) UPC2 chromatogram (detection 340 nm) for (a) chlorpropham-treated cultures and (b) Norflurazon-treated cultures of *D. salina*.
  - (F) Spectral properties of peak RT of 2.86 min for chlorpropham-treated cultures
  - (G) 3D chromatogram over 220-700 nm of carotenoids extract from *D. salina* cultures under red light with 20  $\mu$ M chlorpropham, obtained after separation by HPLC.
  - (H) 3D chromatogram over 220-700 nm of 78903 SIGMA (E/Z)-Phytoene mixture of isomers, ≥95% (HPLC), obtained after separation by HPLC.
  - (I) 3D chromatogram over 220-700 nm of carotenoids extract from *D. salina* cultures under red light with 20  $\mu$ M chlorpropham, with a spike of phytoene standard.

Figure 19 depicts the carotenoid pathway.

Table 1. Effect of different light treatments on the culture concentration of carotenoids and the ratio of 9-cis and all-trans  $\beta$ -carotene in Dunaliella salina when cultivated to early orange phase until light treatment (T0) and then subjected to different light treatments for 48 hours.

All conditions as described in Figure 2. Data were calculated mean values  $\pm$  standard deviations. Each light condition was set up at least in triplicate. Red light whether applied with LED or filters increased yield of carotenes and the ratio of *9-cis: all-trans*  $\beta$ -carotene.

	Cell		Concentrat	ion (μg/ml)		9-cis:all-
Light		All-trans		All-trans	9-cis	trans β-
treatment	density (x10 <sup>6</sup> /ml)	α-	Phytoene	β-	β-	carotene
		carotene		carotene	carotene	ratio
Time 0	0.22±0.01	0.14±0.01	0.08±0.01	2.12±0.10	2.16±0.08	1.02±0.09
White	0.40±0.02	0.31±0.03	0.88±0.11	5.35±0.58	5.01±0.21	0.95±0.14
Red	0.37±0.06	0.27±0.02	1.04±0.06	4.02±0.40	5.76±0.97	1.44±0.27
Blue	0.38±0.03	0.19±0.01	0.67±0.06	4.72±0.25	2.95±0.21	0.63±0.04
White+	0.38±0.01	0.26±0.02	0.64±0.04	3.78±0.44	6.60±0.67	1.75±0.03
filter26	0.36±0.01	0.20±0.02	0.04±0.04	3.76±0. <b>44</b>	0.00±0.07	1.75±0.05
White+	0.41±0.01	0.24±0.05	0.59±0.14	3.93±0.34	7.07±0.58	1.80±0.16
filter27	0.41±0.01	0.24±0.03	0.5514	J.JJ±0.J∓	7.07±0.50	1.00-0.10
White+	0.36±0.02	0.16±0.02	0.27±0.03	2.89±0.32	4.68±0.39	1.62±0.06
filter787	0.30±0.02	0.10±0.02	0.27±0.03	2.09±0.32	7.00±0.33	1,02-0,00

Table 2. Effect of different light treatments on culture concentration of carotenoids and the ratio of 9-cis and all-trans β-carotene in Dunaliella salina when cultivated to mid-log phase of growth until light treatment (T0) and then subjected to different light treatments. All conditions as described in Figure 4. Data were calculated mean values ± standard deviations. Each light condition was set up at least in triplicate. Red LED light increased the entire pathway of carotene production since contents of all carotenoids increased in parallel with the previously reported increases in carotene content described above.

			Concentrat	tion (µg/ml)		
Time	Light	All-trans α-	Dhartoono	All-trans	9-cis	9 <b>-</b> cis:all-trans
		carotene	Phytoene	β-carotene	β-carotene	ratio
Control	White	0.07±0.03	-	0.63±0.16	0.45±0.08	0.71
0	Dark	0.02±0.00	0.07±0.01	0.51±0.08	0.30±0.11	0.59
0-24 h	Red	0.05±0.00	0.16±0.02	0.60±0.07	0.73±0.15	1.22

	Red	0.12±0.04	0.41±0.03	1.12±0.24	1.77±0.26	1.58
24-48 h	Blue	0.06±0.00	0.14±0.03	1.03±0.07	0.53±0.02	0.51
24 40 H	Mix	0.10±0.00	0.21±0.02	1.12±0.03	0.84±0.02	0.75
	Dark	0.06±0.00	0.16±0.01	0.79±0.15	0.82±0.11	1.04

Table 3. Cellular content of carotenoids in *Dunaliella salina* cells treated with either continuous blue or red LED light at three different light intensities of 200, 500 and 1000 μmol m<sup>-2</sup> s<sup>-1</sup> for 48 hours. All conditions as described in Figure 6.

	Intensity		Cellular cont	ent (pg cell <sup>-1</sup> )		9-cis:all-trans
Light	(μmol m <sup>-</sup> <sup>2</sup> s <sup>-1</sup> )	All-trans α-carotene	Phytoene	All-trans β-	9-cis β-carotene	β-carotene ratio
	200	0.68±0.10	1.49±0.26	5.93±0.07	10.04±1.38	1.69
Red	500	0.84±0.13	2.10±0.24	6.80±0.01	11.93±1.59	1.75
	1000	0.66±0.09	2.28±0.45	6.21±0.60	9.75±1.09	1.57
	200	0.34±0.06	0.79±0.19	5.51±1.40	3.98±0.96	0.72
Blue	500	0.47±0.08	1.27±0.25	7.68±1.66	4.79±0.85	0.62
	1000	0.64±0.09	2.23±0.41	10.27±1.23	10.03±1.46	0.98

10

It can be seen from the data presented in Tables 1 to 3, and Figures 1 to 8, that exposure of *Dunaliella salina* to red light results in a significant increase in the content of total carotenoids, particularly an increase in the content of 9-cis- $\beta$ -carotene, and a significant increase in the ratio of 9-cis to *all-trans*  $\beta$ -carotene. The data also show that exposure of *Dunaliella salina* to red light also increased phytoene (a colourless carotenoid) and  $\alpha$ -carotene.

(B) in the presence of either Norflurazon or chlorpropham (CIPC) compared to cultivation without herbicide. Both white and red LED lights were applied at **Table 4** provides a comparison of the contents of carotenoids for cultures of *D. salina* cultivated for 48h under either white LED light (A) or red LED light

200 µmol m<sup>-2</sup> s<sup>-1</sup> continuously for 48 h after adding the herbicides. Red light more than doubled the yield of phytoene in either CIPC or norflurazon-treated cultures, increased the content of total carotenoids, and increased the ratio of 9-cis: all-trans \(\beta\)-carotene. Ŋ

# (A) Cultivation under white LED light (48 h treatment)

carotenoids (pg cell <sup>-1</sup> )	Phytoene	Phyto- fluene	All-trans β-carotene	<i>9-cis</i> β-carotene	zeaxanthin	All-trans α- carotene	lutein	Total carotenoids (sum)	phytoene+ phytofluene of total	9cis of total
No herbicide	0.79±0.04	0.79±0.04 0.07±0.00	6.46±0.10	10.73±0.22	0.90±0.08	0.44±0.02	0.66±0.01	20.05	4%	54%
chlorpropham (10 µM)	4.41±0.65	4.41±0.65 0.67±0.09	10.56±1.57	13.35±1.88	0.84±0.09	0.33±0.02	0.83±0.13	30.99	16%	43%
Norflurazon (5 μM)	7.07±0.36	0.01±0.00	7.07±0.36 0.01±0.00 4.28±0.18	7.65±0.67	0.80±0.07	0.27±0.01	0.52±0.02	20.6	34%	37%

## (B) Cultivation under red light (48 h treatment)

α- lutein carotene	<u> </u>	Zeaxanthin	9-cis β- Zeaxanthin carotene	Zeaxanthin	9-cis β- carotene
2 0.41±0.05 0.69±	12	25 1.17±0.	0 13.40±1.25 1.17±0.	5.58±0.60   13.40±1.25   1.17±0.	0.98±0.02   0.13±0.00   5.58±0.60   13.40±1.25   1.17±0.12   0.41±0.05   0.69±0.04
6 0.51±0.02 0.74±	0.06	24 1.05±	8 14.35±1.24 1.05±	7.91±0.38 14.35±1.24 1.05±	10.56±1.53 1.58±0.17 7.91±0.38 14.35±1.24 1.05±0.06 0.51±0.02 0.74±0.05

45

38%
46%
31.55
0.62±0.02
0.39±0.01
1.12±0.06
11.89±0.83
3.09±0.30
0.02±0.00
14.42±0.95
Norflurazon (5 μM)

**Table 5** shows the contents of carotenoids produced for cultures of D. salina cultivated for 96 h and 144h under red light of varying intensities and different

illumination time, with the application of chlorpropham. Data for diflufenican are also shown.

carotenoids (pg cell <sup>-1</sup> )	Phytoene	Phyto- fluene	<i>All-trans</i> β-carotene	<i>9-cis</i> β- carotene	zeaxanthin	Ail-trans α- carotene	lutein	Total carotenoids (sum)	phytoene+ phytofluene of total	9cis of total
chlorpropham 1500µmol m <sup>.2</sup> s <sup>.1</sup> 96h	30.62±1.31 1.87±0.12 17.34±0.97	1.87±0.12	17.34±0.97	6.96±0.74	0.77±0.02	0.44±0.07	0.61±0.03	58.61	25%	12%
chlorpropham 200µmolm² s <sup>-</sup> 1144h	51.88±4.53 3.02±0.29	3.02±0.29	18.34±1.45	31.3±2.49	1.33±0.10	1.4±0.13	1.21±0.09	108.48	51%	29%
Diflufenican 200µmol m <sup>-2</sup> s <sup>-1</sup> 48h	12.78±0.40 0.01±0.00	0.01±0.00	2.98±0.11	2.98±0.11 10.84±0.19	1.13±0.06	0.34±0.00	0.56±0.01	28.64	45%	38%

### **CLAIMS**

- 1 A Dunaliella alga, or extract thereof, comprising
  - iv. an increased 9-cis β-carotene content and/or
- v. an increased colourless carotenoid content; and/or
  - vi. an increased α-carotene content;

5

30

when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

- 10 2 A powdered *Dunaliella* alga, or extract thereof, comprising:
  - iv. an increased 9-cis β-carotene content and/or
  - v. an increased colourless carotenoid content; and/or
  - vi. an increased α-carotene content;

when compared to a *Dunaliella* alga, or extract thereof, which is grown or cultivated under natural light or white light conditions.

- 3 A Dunaliella alga, or extract thereof; or a powdered Dunaliella alga, or extract thereof; comprising a 9-cis  $\beta$ -carotene content of 60 wt % of total carotenoids or greater.
- 4, A *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding claim, wherein the  $\beta$ -carotene has a *9-cis* : *all-trans* ratio of 2.0 or greater.
- 5. A *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof;
   25 comprising a colourless carotenoid content of 10 wt % of total carotenoids or greater.
  - 6. A *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding claim, comprising a colourless carotenoid content of 40 wt % of total carotenoids or greater.
  - 7. A *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding claim, comprising a phytoene content of 40 wt % of total carotenoids or greater.
- 35 8. A *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding claim, wherein the *Dunaliella* alga is selected from *Dunaliella salina salina*, *Dunaliella salina bardawil* and *Dunaliella salina rubeus*.

9. A composition comprising: a) a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; according to any preceding embodiment; and b) a pharmaceutically acceptable excipient.

5

- 10. A process for the preparation of a *Dunaliella* alga or extract thereof, comprising the steps:
  - a) cultivating the *Dunaliella* alga under white light; and subsequently;
  - b) exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm; and/or eliminating light of wavelength less than 500nm (blue light).

10

- 11. A process according to claim 10, comprising the steps:
  - a) cultivating the *Dunaliella* alga under white light; subsequently;
  - b) exposing the *Dunaliella* alga to light of wavelength 500-1000nm, or 500-700nm or 700-1000nm; and/or eliminating light of wavelength less than 500nm (blue light); and
- applying a herbicide to the *Dunaliella* alga during step a) and/or step b).
  - 12. A process according to claim 11, wherein the herbicide is selected from amino acid synthesis inhibitors, growth regulators, nitrogen metabolism inhibitors, pigment inhibitors, seedling root growth inhibitors, seedling shoot growth inhibitors, cell wall synthesis inhibitors, mitosis microtubule organisation inhibitors, and combinations thereof.
  - 13. A process according to claim 11 or 12, wherein the herbicide is selected from norflurazon, diflufenican, picolinafen, beflubutamid, fluridone, flurochloridone, flurtamone, chlorpropham, propham, carbetamide, and combinations thereof.

25

30


20


- 14. A process for the preparation of a *Dunaliella* alga, comprising applying the *Dunaliella* alga with a herbicide selected from the group consisting of amino acid synthesis inhibitors, growth regulators, nitrogen metabolism inhibitor, pigment inhibitors (excluding phytoene desaturase inhibitors), seedling root growth inhibitors, seedling shoot growth inhibitors, cell wall synthesis inhibitors, mitosis microtubule organisation inhibitors, and combinations thereof.
- 15. A process according to claim 14, wherein the herbicide is selected from chlorpropham, propham, carbetamide, and combinations thereof.
- 35 16. Use of a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; as defined in any one of claims 1 to 8, as a food colourant or food ingredient; or as a health supplement.

- 17. Use of a *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof, as defined in any one of claims 1 to 8 in a cosmetic composition.
- 5 18. A *Dunaliella* alga, or extract thereof; or a powdered *Dunaliella* alga, or extract thereof; as defined in any one of claims 1 to 8; or a composition as defined in claim 9, for use in therapy.


FIGURE 1

 $\mathbf{A}$ 







 $\mathbf{C}$ 



### FIGURE 2


 $\mathbf{A}$ 






### FIGURE 2

 $\mathbf{C}$ 



### FIGURE 3

 $\mathbf{A}$ 







FIGURE 4

 $\mathbf{A}$ 








FIGURE 5


 $\mathbf{A}$ 






### FIGURE 5

 $\mathbf{C}$ 



### FIGURE 6

 $\mathbf{A}$ 








FIGURE 6

 $\mathbf{C}$ 



D



### FIGURE 6

 $\mathbf{E}$ 






FIGURE 7


 $\mathbf{A}$ 






### FIGURE 7


 $\mathbf{C}$ 



## FIGURE 8


 $\mathbf{A}$ 






### FIGURE 9

 $\mathbf{A}$ 




B




15/51

### FIGURE 9

 $\mathbf{C}$ 




D



16/51

### FIGURE 9

 $\mathbf{E}$ 



 $\mathbf{F}$ 






FIGURE 10

A





## FIGURE 10

C





FIGURE 11

Dunaliella Classification








FIGURE 12


21/51



22/51




23/51



24/51

FIGURE 13

 $\mathbf{A}$ 



В





FIGURE 13

 $\mathbf{C}$ 



D






FIGURE 13

 $\mathbf{E}$ 




#### FIGURE 14

 $\mathbf{A}$ 




В



**FIGURE 14** 

 $\mathbf{C}$ 



D






FIGURE 14

 $\mathbf{E}$ 




### FIGURE 15

A




В




### FIGURE 15

 $\mathbf{C}$ 



D



# FIGURE 15

 $\mathbf{E}$ 







FIGURE 16

A











FIGURE 16

В







FIGURE 16

 $\mathbf{C}$ 








FIGURE 16


D






#### FIGURE 17


A





### FIGURE 17

В



# FIGURE 18

A






FIGURE 18B



43/51




44/51

FIGURE 18

# FIGURE 18


D




45/51



 $\Box$ 




46/51



47/51

# FIGURE 18


G



48/51

# FIGURE 18


 $\mathbf{H}$ 




49/51

# FIGURE 18

Ι



#### FIGURE 19



International application No PCT/GB2018/053278

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K36/05 C12N1/12 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K C12R C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, Sequence Search, EMBASE, WPI Data, COMPENDEX

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GARCIA-GONZALEZ M ET AL: "Production of Dunaliella salina biomass rich in 9-cis-@b-carotene and lutein in a closed tubular photobioreactor", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 115, no. 1, 12 January 2005 (2005-01-12), pages 81-90, XP004966991, ISSN: 0168-1656, DOI: 10.1016/J.JBIOTEC.2004.07.010 abstract page 86, left-hand column, line 3 - right-hand column, line 2 page 82, left-hand column, line 1 - line 12	1,3,8 2,9, 16-18

X Further documents are listed in the continuation of Box C.	X See patent family annex.			
* Special categories of cited documents :				
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other	step when the document is taken alone			
special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art			
"O" document referring to an oral disclosure, use, exhibition or other means				
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
10 January 2019	30/01/2019			
Name and mailing address of the ISA/	Authorized officer			
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Mundel, Christophe			

1

International application No
PCT/GB2018/053278

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
ORSET SANDRA ET AL: "Low-temperature-induced synthesis of alpha-carotene in the microalga Dunaliella salina (Chlorophyta)", JOURNAL OF PHYCOLOGY, vol. 35, no. 3, June 1999 (1999-06), pages 520-527, XP002787804,	1,8
abstract	2,9, 16-18
ORSET SANDRA CHARLOTTE ET AL: "Exposure to low irradiances favors the synthesis of 9-cis beta, beta-carotene in Dunaliella salina (Teod.)", PLANT PHYSIOLOGY (ROCKVILLE), vol. 122, no. 2, February 2000 (2000-02), pages 609-617, XP002787805,	1,3-8
abstract	2,9, 11-13, 16-18
KR 2014 0044419 A (KOREA INST OCEAN SCI &	1,8,10
TECH [KR]) 15 April 2014 (2014-04-15) paragraph [0028] claim 7	11-13
KR 2002 0012351 A (BINEX CO LTD [KR]; CHO MAN GI [KR]; KIM WON SUK [KR]) 16 February 2002 (2002-02-16) paragraph [0014]	1,8
JOSÉ A DEL CAMPO ET AL: "Outdoor cultivation of microalgae for carotenoid production: current state and perspectives", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 74, no. 6, 3 February 2007 (2007-02-03), pages 1163-1174, XP019513668, ISSN: 1432-0614, DOI: 10.1007/S00253-007-0844-9 page 1165, left-hand column, line 10 - line 25	2,9, 16-18
	ORSET SANDRA ET AL: "Low-temperature-induced synthesis of alpha-carotene in the microalga Dunaliella salina (Chlorophyta)", JOURNAL OF PHYCOLOGY, vol. 35, no. 3, June 1999 (1999-06), pages 520-527, XP002787804, ISSN: 0022-3646 abstract  ORSET SANDRA CHARLOTTE ET AL: "Exposure to low irradiances favors the synthesis of 9-cis beta,beta-carotene in Dunaliella salina (Teod.)", PLANT PHYSIOLOGY (ROCKVILLE), vol. 122, no. 2, February 2000 (2000-02), pages 609-617, XP002787805, ISSN: 0032-0889 abstract  KR 2014 0044419 A (KOREA INST OCEAN SCI & TECH [KR]) 15 April 2014 (2014-04-15) paragraph [0028] claim 7  KR 2002 0012351 A (BINEX CO LTD [KR]; CHO MAN GI [KR]; KIM WON SUK [KR]) 16 February 2002 (2002-02-16) paragraph [0014]  JOSÉ A DEL CAMPO ET AL: "Outdoor cultivation of microalgae for carotenoid production: current state and perspectives", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 74, no. 6, 3 February 2007 (2007-02-03), pages 1163-1174, XP019513668, ISSN: 1432-0614, D01: 10.1007/S00253-007-0844-9

International application No PCT/GB2018/053278

C(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	MYSORE DODDAIAH K ET AL: "Effect of metabolic inhibitors on growth and carotenoid production in Dunaliella bardawil", JOURNAL OF FOOD SCIENCE AND TECHNOLOGY DECEMBER 2013 SPRINGER INDIA IND, vol. 50, no. 6, December 2013 (2013-12), pages 1130-1136, XP002787806, DOI: 10.1007/S13197-011-0429-6	14,15	
Υ	abstract	11-13	
Y	HARARI AYELET ET AL: "A 9-cis beta-carotene-enriched diet inhibits atherogenesis and fatty liver formation in LDL receptor knockout mice.", THE JOURNAL OF NUTRITION OCT 2008, vol. 138, no. 10, October 2008 (2008-10), pages 1923-1930, XP002787807, ISSN: 1541-6100 abstract	2,9,16, 18	

1

Information on patent family members

International application No
PCT/GB2018/053278

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
KR 20140044419 A	15-04-2014	NONE	
KR 20020012351 A	16-02-2002	NONE	